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A B S T R A C T
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic present important diagnostic
challenges. Several diagnostic strategies are available to identify or rule out current infection, identify people in need of care escalation,
or to test for past infection and immune response. Point-of-care antigen and molecular tests to detect current SARS-CoV-2 infection have
the potential to allow earlier detection and isolation of confirmed cases compared to laboratory-based diagnostic methods, with the aim
of reducing household and community transmission.
Objectives
To assess the diagnostic accuracy of point-of-care antigen and molecular-based tests to determine if a person presenting in the community
or in primary or secondary care has current SARS-CoV-2 infection.
Search methods
On 25 May 2020 we undertook electronic searches in the Cochrane COVID-19 Study Register and the COVID-19 Living Evidence Database
from the University of Bern, which is updated daily with published articles from PubMed and Embase and with preprints from medRxiv
and bioRxiv. In addition, we checked repositories of COVID-19 publications. We did not apply any language restrictions.
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Selection criteria
We included studies of people with suspected current SARS-CoV-2 infection, known to have, or not to have SARS-CoV-2 infection, or where
tests were used to screen for infection. We included test accuracy studies of any design that evaluated antigen or molecular tests suitable
for a point-of-care setting (minimal equipment, sample preparation, and biosafety requirements, with results available within two hours of
sample collection). We included all reference standards to define the presence or absence of SARS-CoV-2 (including reverse transcription
polymerase chain reaction (RT-PCR) tests and established clinical diagnostic criteria).
Data collection and analysis
Two review authors independently screened studies and resolved any disagreements by discussion with a third review author. One review
author independently extracted study characteristics, which were checked by a second review author. Two review authors independently
extracted 2x2 contingency table data and assessed risk of bias and applicability of the studies using the QUADAS-2 tool. We present
sensitivity and specificity, with 95% confidence intervals (CIs), for each test using paired forest plots. We pooled data using the bivariate
hierarchical model separately for antigen and molecular-based tests, with simplifications when few studies were available. We tabulated
available data by test manufacturer.
Main results
We included 22 publications reporting on a total of 18 study cohorts with 3198 unique samples, of which 1775 had confirmed SARS-
CoV-2 infection. Ten studies took place in North America, two in South America, four in Europe, one in China and one was conducted
internationally. We identified data for eight commercial tests (four antigen and four molecular) and one in-house antigen test. Five of the
studies included were only available as preprints.
We did not find any studies at low risk of bias for all quality domains and had concerns about applicability of results across all studies. We
judged patient selection to be at high risk of bias in 50% of the studies because of deliberate over-sampling of samples with confirmed
COVID-19 infection and unclear in seven out of 18 studies because of poor reporting. Sixteen (89%) studies used only a single, negative RT-
PCR to confirm the absence of COVID-19 infection, risking missing infection. There was a lack of information on blinding of index test (n =
11), and around participant exclusions from analyses (n = 10). We did not observe di&erences in methodological quality between antigen
and molecular test evaluations.
Antigen tests
Sensitivity varied considerably across studies (from 0% to 94%): the average sensitivity was 56.2% (95% CI 29.5 to 79.8%) and average
specificity was 99.5% (95% CI 98.1% to 99.9%; based on 8 evaluations in 5 studies on 943 samples). Data for individual antigen tests were
limited with no more than two studies for any test.
Rapid molecular assays
Sensitivity showed less variation compared to antigen tests (from 68% to 100%), average sensitivity was 95.2% (95% CI 86.7% to 98.3%)
and specificity 98.9% (95% CI 97.3% to 99.5%) based on 13 evaluations in 11 studies of on 2255 samples. Predicted values based on a
hypothetical cohort of 1000 people with suspected COVID-19 infection (with a prevalence of 10%) result in 105 positive test results including
10 false positives (positive predictive value 90%), and 895 negative results including 5 false negatives (negative predictive value 99%).
Individual tests
We calculated pooled results of individual tests for ID NOW (Abbott Laboratories) (5 evaluations) and Xpert Xpress (Cepheid Inc) (6
evaluations). Summary sensitivity for the Xpert Xpress assay (99.4%, 95% CI 98.0% to 99.8%) was 22.6 (95% CI 18.8 to 26.3) percentage
points higher than that of ID NOW (76.8%, (95% CI 72.9% to 80.3%), whilst the specificity of Xpert Xpress (96.8%, 95% CI 90.6% to 99.0%)
was marginally lower than ID NOW (99.6%, 95% CI 98.4% to 99.9%; a di&erence of −2.8% (95% CI −6.4 to 0.8))
Authors' conclusions
This review identifies early-stage evaluations of point-of-care tests for detecting SARS-CoV-2 infection, largely based on remnant laboratory
samples. The findings currently have limited applicability, as we are uncertain whether tests will perform in the same way in clinical
practice, and according to symptoms of COVID-19, duration of symptoms, or in asymptomatic people. Rapid tests have the potential to be
used to inform triage of RT-PCR use, allowing earlier detection of those testing positive, but the evidence currently is not strong enough
to determine how useful they are in clinical practice.
Prospective and comparative evaluations of rapid tests for COVID-19 infection in clinically relevant settings are urgently needed. Studies
should recruit consecutive series of eligible participants, including both those presenting for testing due to symptoms and asymptomatic
people who may have come into contact with confirmed cases. Studies should clearly describe symptomatic status and document time
from symptom onset or time since exposure. Point-of-care tests must be conducted on samples according to manufacturer instructions for
use and be conducted at the point of care. Any future research study report should conform to the Standards for Reporting of Diagnostic
Accuracy (STARD) guideline.
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)










Cochrane Database of Systematic Reviews
P L A I N   L A N G U A G E   S U M M A R Y
How accurate are rapid tests, performed during a health-care visit (point-of-care), for diagnosing COVID-19?
Why is this question important?
People with suspected COVID-19 need to know quickly whether they are infected, so that they can self-isolate, receive treatment, and
inform close contacts. Currently, COVID-19 infection is confirmed by sending away samples, taken from the nose and throat, for laboratory
testing. The laboratory test, called RT-PCR, requires specialist equipment, may require repeat healthcare visits, and typically takes at least
24 hours to produce a result.
Rapid point-of-care tests can provide a result ‘while you wait’, ideally within two hours of providing a sample. This could help people isolate
early and reduce the spread of infection.
What did we want to find out?
We were interested in two types of rapid point-of-care tests, antigen and molecular tests. Antigen tests identify proteins on the virus, o-en
using disposable devices. Molecular tests detect the virus’s genetic material, using small portable or table-top devices. Both test the same
nose or throat samples as RT-PCR tests.
We wanted to know whether rapid point-of-care antigen and molecular tests are accurate enough to replace RT-PCR for diagnosing
infection, or to select people for further testing if they have a negative result.
What did we do?
We looked for studies that measured the accuracy of rapid point-of-care tests compared with RT-PCR tests to detect current COVID-19
infection. Studies could assess any rapid antigen or molecular point-of-care test, compared with a reference standard test. The reference
standard is the best available method for diagnosing the infection; we considered RT-PCR test results and clinically defined COVID-19 as
reference tests. People could be tested in hospital or the community. Studies could test people with or without symptoms.
Tests had to use minimal equipment, be performed safely without risking infection from the sample, and have results available within
two hours of the sample being collected. Tests could be used in small laboratories or wherever the patient is (in primary care, urgent care
facilities, or in hospital).
How did studies assess diagnostic test accuracy?
Studies tested participants with the rapid point-of-care tests. Participants were classified as known to have – and not to have - COVID-19, by
RT-PCR in all studies. Studies then identified false positive and false negative errors in the point-of-care test results, compared to RT-PCR.
False positive tests incorrectly identified COVID-19 when it was not present, potentially leading to unnecessary self-isolation and further
testing. False negatives missed COVID-19 when it was present, risking delayed self-isolation and treatment, and spread of infection.
What we found
We found 18 relevant studies. Ten studies took place in North America, four in Europe, two in South America, one in China and one in
multiple countries.
Nine studies deliberately included a high percentage of people with confirmed COVID-19 or included only people with COVID-19. Fourteen
studies did not provide any information about the people providing the samples for testing and 12 did not provide any information about
where people were tested.
None of the studies reported includedsamples from people without symptoms.
Main results
Five studies reported eight evaluations of five di&erent antigen tests. Overall, there was considerable variation between the results of the
antigen tests in how well they detected COVID-19 infection. Tests gave false positive results in less than 1% of samples.
Thirteen evaluations of four di&erent molecular tests correctly detected an average of 95% of samples with COVID-19 infection. Around
1% of samples gave false positive results.
If 1000 people had molecular tests, and 100 (10%) of them really had COVID-19:
- 105 people would test positive for COVID-19. Of these, 10 people (10%) would not have COVID-19 (false positive result).
- 895 people would test negative for COVID-19. Of these, 5 people (1%) would actually have COVID-19 (false negative result).
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We noted a large di&erence in COVID-19 detection between the two most commonly evaluated molecular tests.
How reliable were the results of the studies?
Our confidence in the evidence is limited.
- Three-quarters of studies did not follow the test manufacturers’ instructions, so may have found di&erent results if they had.
- O-en, studies did not use the most reliable methods or did not report enough information for us to judge their methods. This may have
a&ected estimates of test accuracy, but it is impossible to identify by how much.
- A quarter of studies were published early online as ‘preprints’ and are included in the review. Preprints do not undergo the normal rigorous
checks of published studies, so we are uncertain how reliable they are.
What are the implications of this review?
Studies provided little information about their participants, so it is not possible to tell if the results can be applied to people with no
symptoms, mild symptoms, or who were hospitalised with COVID-19. Accurate rapid tests would have the potential to select people for
RT-PCR testing or to be used where RT-PCR is not available. However, the evidence currently is not strong enough and more studies are
urgently needed to be able to say if these tests are good enough to be used in practice.
How up-to-date is this review?
This review includes evidence published up to 25 May 2020. Because new research is being published in this field, we will update this
review soon.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Diagnostic accuracy of point-of-care antigen and molecular-based tests for the diagnosis of SARS-CoV-2 infection
Question What is the diagnostic accuracy of rapid point-of-care antigen and molecular-based tests for the diagnosis of SARS-CoV-2 infection?
Population Adults or children suspected of:
• current SARS-CoV-2 infection
or populations undergoing screening for SARS-CoV-2 infection, including
• asymptomatic contacts of confirmed COVID-19 cases
• community screening
Index test Any rapid antigen or molecular-based test for diagnosis of SARS-CoV-2 meeting the following criteria:
• portable or mains-powered device
• minimal sample preparation requirements
• minimal biosafety requirements
• no requirement for a temperature-controlled environment
• test results available within 2 hours of sample collection
Target condi-
tion
Detection of current SARS-CoV-2 infection
Reference
standard
For COVID-19 cases: positive RT-PCR alone or clinical diagnosis of COVID-19 based on established guidelines or combinations of clinical features
For non-COVID-19 cases: repeated negative RT-PCR or pre-pandemic sources of samples
Action False negative results mean missed cases of COVID-19 infection, with either delayed or no confirmed diagnosis and increased risk of community trans-
mission due to false sense of security
False positive results lead to unnecessary self-isolation or quarantine, with the potential for new infection to be acquired
Number of studies Total samples Total samples with confirmed SARS-CoV-2Quantity of ev-
idence
18 3198 1775
Limitations in the evidence
Risk of bias Participants: high or unclear risk in 16 studies (89%)























































































































































































Reference standard: unclear risk in 10 studies (56%)




Participants: high concerns in 13 studies (72%)
Index test: high concerns in 13 studies (72%)





Samples Confirmed SARS-CoV-2 samples Average sensitivity (95% CI)
[Range]
Average specificity (95% CI)
[Range]
8 (5) 943 596 56.2 (29.5 to 79.8)
[0% to 94%]a
99.5 (98.1 to 99.9)
[90% to 100%]
Average sensitivity and specificity applied to a hypothetical cohort of 1000 patients a
Prevalence of
COVID-19
TP FP FN TN PPV b NPV c
5% 28a 5 22a 945 85% (68% to 95%)a 98% (97% to 99%)
10% 56a 5 44a 896 92% (82% to 97%)a 95% (94% to 97%)a




Samples Confirmed SARS-CoV-2 samples Average sensitivity (95% CI)
[Range]
Average specificity (95% CI)
[Range]
13 (11) 2255 1179 95.2 (86.7 to 98.3)
[68% to 100%]
98.9 (97.3 to 99.5)
[92% to 100%]

























































































































































































TP FP FN TN PPV b (95% CI) NPV c (95% CI)
5% 48 10 2 940 83% (71% to 91%) 100% (99% to 100%)
10% 95 10 5 890 90% (83% to 95%) 99% (99% to 100%)
20% 190 9 10 791 95% (92% to 98%) 99% (98% to 99%)
Pooled results for individual tests
Tests Evaluations Samples SARS-CoV-2
cases




2 238 162 89.5 (83.7 to 93.8) 100 (95.3 to 100)
ID NOW 5 1003 496 76.8 (72.9 to 80.3) 99.6 (98.4 to 99.9)
Xpert Xpress 6 919 479 99.4 (98.0 to 99.8) 96.8 (90.6 to 99.0)
Average sensitivity and specificity applied to a hypothetical cohort of 1000 patients where 100 have COVID-19 infection (10% prevalence)




90 0 11 900 100% (96% to 100%) 99% (98% to 99%)
ID NOW 77 4 23 896 96% (89% to 99%) 97% (96% to 98%)
Xpert Xpress 99 29 1 871 77% (69% to 84%) 100% (99% to 100%)
Ag: antigen;CI: confidence interval; FN: false negative; FP: false positive;NPV: negative predictive value; PPV: positive predictive value; RT-PCR: reverse transcription poly-
merase chain reaction; TN: true negative; TP: true positive
aAs there is high heterogeneity in the estimates of sensitivity, the values observed in practice could vary considerably from these figures.
bPPV (positive predictive value) defined as the percentage of positive rapid test results that are truly positive according to the reference standard diagnosis.
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B A C K G R O U N D
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
the resulting COVID-19 pandemic present important diagnostic
evaluation challenges. These range from: understanding the value
of signs and symptoms in predicting possible infection; assessing
whether existing biochemical and imaging tests can identify
infection or people needing critical care; and evaluating whether
new biomarker tests can accurately identify current infection, rule
out infection, identify people in need of care escalation, or test for
past infection and immunity.
We are creating and maintaining a suite of living systematic
reviews to cover the roles of tests and patient characteristics in
the diagnosis of COVID-19. This review summarises evidence for
the accuracy of rapid antigen and molecular tests, suitable for use
at the point of care, as alternatives to standard laboratory-based
reverse transcription polymerase chain reaction (RT-PCR), that are
relied on for identifying current infection. If su&iciently accurate,
point-of-care tests may have a greater impact on public health
than RT-PCR as they do not require the same technical expertise
and laboratory capacity. These tests can be undertaken locally,
avoiding the need for centralised testing facilities that rarely meet
the needs of patients, caregivers, health workers and society as a
whole, especially in low- and middle-income countries. As these are
rapid tests, their results can be returned within the same clinical
encounter, facilitating timely decisions concerning the need for
isolation.
Target condition being diagnosed
COVID-19 is the disease caused by infection with the SARS-CoV-2
virus. The key target conditions for this suite of reviews are current
SARS-CoV-2 infection, current COVID-19 disease, and past SARS-
CoV-2 infection. The tests included in this review concern the
identification of current infection.
For current infection, the severity of the disease is of importance.
SARS-CoV-2 infection can be asymptomatic (no symptoms); mild
or moderate (symptoms such as fever, cough, aches, lethargy
but without di&iculty breathing at rest); severe (symptoms
with breathlessness and increased respiratory rate indicative of
pneumonia); or critical (requiring respiratory support due to severe
acute respiratory syndrome (SARS) or acute respiratory distress
syndrome (ARDS). People with COVID-19 pneumonia (severe or
critical disease) require di&erent patient management, and it is
important to be able to identify them. Viral load may also be an
indicator of disease severity (Zheng 2020), and whilst the accuracy
of antigen and molecular tests have the potential to be a&ected
by participant viral load, the main aim of rapid testing is not to
establish viral load. In this review, we therefore consider the role
of point-of-care tests for detecting SARS-CoV-2 infection of any
severity.
Index test(s)
The primary consideration for the eligibility of tests for inclusion in
this review is that they should detect current infection and should
have the capacity to be performed at the ‘point of care’ or in a ‘near-
patient’ testing role. There is an ongoing debate around the specific
use and definitions of these terms, therefore for the purposes of
this review, we consider ‘point-of-care’ and ‘near patient’ to be
synonymous, but for consistency and avoidance of confusion, we
use the term ‘point-of-care’ throughout.
We have adapted a definition of point-of-care testing, namely that
it “refers to decentralized testing that is performed by a minimally
trained healthcare professional near a patient and outside of
central laboratory testing” (WHO 2018), with the additional caveat
that test results must be available within a single clinical encounter
(Pai 2012). The key criteria for test inclusion are therefore:
• the equipment for running and or reading the assay must be
portable or easily transported, although mains power may be
required;
• minimal sample preparation requirements, for example, single-
step mixing, with no requirement for additional equipment or
precise sample volume transfer unless a disposable automatic
fill or graduated transfer device is used;
• minimal biosafety requirements, for example, personal
protective equipment (PPE) for sample collector and test
operator, good ventilation and a biohazard bag for waste
disposal;
• no requirement for a temperature-controlled environment; and
• test results available within two hours of sample collection.
Tests for detection of current infection that are currently suitable
for use at the point of care include antigen tests and molecular-
based tests. Both types of test use the same respiratory-tract
samples acquired by swabbing, washing or aspiration as for
laboratory-based RT-PCR. Rapid antigen tests use lateral flow
immunoassays, which are disposable devices, usually in the form
of plastic cassettes akin to a pregnancy test. Viral antigen is
captured by dedicated antibodies that are either colloidal gold- or
fluorescent-labelled. Antigen detection is indicated by visible lines
appearing on the test strip (colloidal gold-based immunoassays,
or CGIA), or through fluorescence, which can be detected using
an immunofluorescence analyser (fluorescence immunoassays
or FIA). Molecular-based tests to detect viral ribonucleic acid
(RNA) have historically been laboratory-based assays using RT-PCR
technology (see Alternative test(s)). In recent years, automated,
single-step RT-PCR methods have been developed, as well as
other nucleic acid amplification methods, such as isothermal
amplification, that do not require the sophisticated thermo cycling
involved in RT-PCR (Carter 2020). These technological advances
have allowed molecular technologies to be developed that are
suitable for use in a point-of-care context (Kozel 2017).
Following the emergence of COVID-19 there has been prolific
industry activity to develop accurate tests. The Foundation for
Innovative Diagnostics (FIND) and Johns Hopkins Centre for Health
Security have maintained online lists of these and other molecular-
based tests for SARS-CoV-2 (FIND 2020). At the time of writing
(19 July 2020), FIND listed 48 rapid antigen tests, 32 of which are
described as "commercialized" and 21 have been identified as
having regulatory approval. A total of 113 molecular tests were
described as automated, including both laboratory-based assays
and assays suitable for use outside of a laboratory setting (i.e. near
or at the point of care). Further information from FIND indicates
that 47 of the 113 assays were categorised as point-of-care or
near point-of-care tests, including 26 with regulatory approval. This
classification was based on the information provided to FIND by the
test manufacturers and does not necessarily mean that these tests
meet the criteria for point-of-care tests that we have specified for
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)
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this review. The numbers of tests of these types will increase over
time.
Clinical pathway
Patients may be tested for infection when they present with
symptoms, or have had known exposure to COVID-19, or during
screening for COVID-19. The standard approach to diagnosis of
COVID-19 infection is through laboratory-based testing of swab
samples taken from the upper respiratory (e.g. nasopharynx,
oropharynx) or lower respiratory tract (e.g. bronchoalveolar lavage
or sputum) with RT-PCR. RT-PCR is the primary method for
detecting infection during the acute phase of the illness while
the virus is still present (whether people are symptomatic or
asymptomatic), but can give false negative results (Arevalo-
Rodriguez 2020). Both the World Health Organiation (WHO) and the
China CDC (National Health Commission of the People's Republic
of China), have produced case definitions for COVID-19 that include
the presence of convincing clinical evidence when RT-PCR is
negative (Appendix 1). The most recent case definition from the
China CDC also includes positive serology tests.
Prior test(s)
Signs and symptoms are used in the initial diagnosis of suspected
COVID-19 infection and to help identify those who require a test
for RT-PCR. A number of key symptoms have been associated
with mild to moderate COVID-19, including: troublesome dry
cough (for example, coughing more than usual over a one-hour
period, or three or more coughing episodes in 24 hours), fever
greater than 37.8 °C, diarrhoea, headache, breathlessness on light
exertion, muscle pain, fatigue, and loss of sense of smell and taste.
However, the recently published review of signs and symptoms
found good evidence for the accuracy for these symptoms alone or
in combination to be lacking (Struyf 2020).
Where people are asymptomatic but are being tested on the basis
of epidemiological risk factors, such as exposure to someone with
confirmed SARS-CoV-2, no prior tests will have been conducted.
Role of index test(s)
For most settings in which testing for acute SARS-CoV-2 infection
takes place, results of laboratory-based RT-PCR tests are unlikely
to be available within a single clinical encounter. Point-of-care
tests potentially have a role either as a replacement for RT-PCR
(if su&iciently accurate), or as a means of triaging and rapid
management (quarantine or treatment, or both), with confirmatory
RT-PCR testing for negative results. Obtaining quick results within
a healthcare visit will allow more appropriate decisions about
isolation and healthcare interventions. If accurate, tests may also
be considered for screening at-risk populations, for example in
airport settings or in local outbreaks.
Alternative test(s)
This review is one of seven planned reviews that cover the range
of tests and characteristics being considered in the management of
COVID-19 (Deeks 2020; McInnes 2020). Full details of the alternative
tests and evidence of their accuracy will be summarised in these
reviews. Tests that might be considered as alternatives to point-of-
care tests are considered here.
Laboratory-based molecular tests
RT-PCR tests for SARS-CoV-2 identify viral ribonucleic acid (RNA).
Reagents for RT-PCR were rapidly produced once the viral RNA
sequence was published (Corman 2020). Testing is undertaken in
central laboratories and can be very labour-intensive, with several
points along the path of performing a single test where errors
may occur, although some automation of parts of the process
is possible. The amplification process requires thermal cycling
equipment to allow multiple temperature changes within a cycle,
with cycles repeated up to 40 times until viral DNA is detected
(Carter 2020). Although the amplification process for RT-PCR can be
completed in a relatively short timeframe, the stages of extraction,
sample processing and data management (including reporting)
mean that test results are typically only available in 24 to 48
hours. Where testing is undertaken in a centralised laboratory,
transport times increase this further. The time to result for fully
automated RT-PCR assays is shorter than for manual RT-PCR,
however most assays still require sample preparation steps that
make them unsuitable for use at the point of care. Other nucleic
acid amplification methods, including loop-mediated isothermal
amplification (LAMP), or CRISPR-based nucleic acid detection
methods, that allow amplification at a constant temperature are
also being developed (Carter 2020). These methods have the
potential to reduce the time to produce test results a-er extraction
and sample processing to minutes, but the time for the whole
process may still be significant. Laboratory-based molecular tests
are most o-en applied to upper and lower respiratory samples
although they are also being used on faecal and urine samples.
Antibody tests
Serology tests to measure antibodies to SARS-CoV-2 have been
evaluated in people with active infection and in convalescent cases
(Deeks 2020a). Antibodies are formed by the body's immune system
in response to infections, and can be detected in whole blood,
plasma or serum. Antibody tests are available for laboratory use
including enzyme-linked immunosorbent assay (ELISA) methods,
or more advanced chemiluminescence immunoassays (CLIA).
There are also rapid lateral flow assays (LFA)s for antibody testing
that use a minimal amount of whole blood, plasma or serum on
a testing strip as opposed to the respiratory specimens that are
used for rapid antigen tests; all assays for antibody detection are
considered in Deeks 2020a.
Rationale
It is essential to understand the clinical accuracy of tests and
diagnostic features to identify the best way they can be used in
di&erent settings to develop e&ective diagnostic and management
pathways. The suite of Cochrane 'living systematic reviews'
summarises evidence on the clinical accuracy of di&erent tests and
diagnostic features, grouped according to the research questions
and settings that we are aware of. Estimates of accuracy from
these reviews will help inform diagnosis, screening, isolation, and
patient-management decisions.
As the COVID-19 pandemic progresses, earlier, fast and reliable
detection of active SARS-CoV-2 infection is key to reducing
community transmission. New biomarker tests are being
developed and evidence is accumulating at an unprecedented
rate. Point-of-care testing provides a potentially attractive route to
increasing testing rates; however their potential to have an impact
on patient care and help reduce transmission depends not only on
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the time it takes to report the test result, but on test performance
and frequency of testing. We are aware of two other reviews on
this topic (Green 2020; Subsoontorn 2020). One rapid review of
point-of-care tests relied on performance data from manufacturers’
instructions for use documents (Green 2020). A systematic review
of nucleic acid amplification ‘point-of-care tests’ selected studies
for inclusion based on the use of isothermal techniques (i.e. not
requiring thermal cycling), with apparently no consideration for
the feasibility of deploying the tests in a point-of-care environment
(Subsoontorn 2020). A comprehensive systematic review of the
clinical performance of tests suitable for use at the point of care
is therefore urgently needed. We will update this review as o-en
as is feasible to ensure that it provides current evidence about the
accuracy of point-of-care tests.
Please note, this review follows a generic protocol that covers six
of the seven Cochrane COVID-19 DTA reviews (Deeks 2020). The
Background and Methods sections of this review therefore use
some text that was originally published in the protocol (Deeks
2020), and text that overlaps some of our other reviews (Deeks
2020a; Struyf 2020).
O B J E C T I V E S
To assess the diagnostic accuracy of rapid point-of-care antigen and
molecular-based tests to determine if a person presenting in the
community or in primary or secondary care has current SARS-CoV-2
infection.
Secondary objectives
Where data are available, we will investigate potential sources
of heterogeneity that may influence diagnostic accuracy (either
by stratified analysis or meta-regression) according to index test,
participant characteristics (length and severity of symptoms, and
viral load), study setting, study design and reference standard used.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We applied broad eligibility criteria in order to include all patient
groups (that is, if patient population was unclear, we included the
study) and all variations of a test.
We included studies of all designs that produce estimates of test
accuracy or provide data from which we can compute estimates,
including the following.
• Studies restricted to participants confirmed to either have (or
to have had) the target condition (to estimate sensitivity) or
confirmed not to have (or have had) the target condition (to
estimate specificity). These types of studies may be excluded in
later review updates.
• Single-group studies, which recruit participants before disease
status has been ascertained.
• Multi-group studies, where people with and without the target
condition are recruited separately (o-en referred to as two-gate
or diagnostic case-control studies).
• Studies based on either patients or samples.
We excluded studies from which we could not extract data to
compute either sensitivity or specificity.
We carefully considered the limitations of di&erent study designs in
the quality assessment and analyses.
We included studies reported in published articles and as preprints.
Participants
We included studies recruiting people presenting with suspicion of
current SARS-CoV-2 infection or those recruiting populations where
tests were used to screen for disease (for example, contact tracing
or community screening).
We also included studies that recruited people known to have
SARS-CoV-2 infection and known not to have SARS-CoV-2 infection
(i.e. cases only or multi-group studies).
We excluded small studies with fewer than 10 samples or
participants. Although the size threshold of 10 is arbitrary, such
small studies are likely to give unreliable estimates of sensitivity or
specificity and may be biased.
Index tests
We included studies evaluating any rapid antigen or molecular-
based test for diagnosis of SARS-CoV-2, if it met the criteria outlined
in the Background, that is, requiring minimal equipment, sample
preparation, and biosafety considerations, with results available
within two hours of sample collection.
Target conditions
The target condition was current SARS-CoV-2 infection (either
symptomatic or asymptomatic). We also refer to SARS-CoV-2
infection as ‘COVID-19 infection’.
Reference standards
We anticipated that studies would use a range of reference
standards to define both the presence and absence of SARS-
CoV-2 infection but were unclear at the start of the review exactly
what methods we would encounter. For the QUADAS-2 (Quality
Assessment tool for Diagnostic Accuracy Studies; Whiting 2011),
assessment we categorised each method of defining the presence
of SARS-CoV-2 according to the risk of bias (the chances that
it would misclassify the presence or absence of infection) and
whether it defined COVID-19 in an appropriate way that reflected
cases encountered in practice. Likewise, we considered the risk of
bias in definitions of the absence of SARS-CoV-2, and whether the
definition included all those who would be tested in practice.
Evaluations of molecular tests generally consider agreement
between molecular assays, for example, agreement of a new rapid
test against a more standard RT-PCR test. For the purposes of
this review, we considered RT-PCR to be the ‘reference standard’
against which the rapid tests were compared, and present results as
‘sensitivity’ and ’specificity’ as opposed to percentage agreement.
The result of further RT-PCR analysis of discrepant cells (samples
with results disagreeing on the rapid test and the RT-PCR) were also
considered in sensitivity analyses. As discrepant analysis involves
retesting only a subsample of patients selected according to index
and reference standard results, it can introduce bias (Hadgu 1999).
Retesting of all samples with a second test in a composite reference
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)










Cochrane Database of Systematic Reviews
standard would be preferable when there are concerns over the
accuracy of the first reference test.
Search methods for identification of studies
Electronic searches
We conducted a single literature search to cover our suite of
Cochrane COVID-19 diagnostic test accuracy (DTA) reviews (Deeks
2020; McInnes 2020).
We conducted electronic searches using two primary sources. Both
of these searches aimed to identify all published articles and
preprints related to COVID-19, and were not restricted to those
evaluating biomarkers or tests. Thus, there are no test terms,
diagnosis terms, or methodological terms in the searches. Searches
were limited to 2019 and 2020, and for this version of the review
have been conducted to 25 May 2020.
Cochrane COVID-19 Study Register searches
We used the Cochrane COVID-19 Study Register
(covid-19.cochrane.org/), for searches conducted from inception
of the Register to 28 March 2020. At that time, the register was
populated by searches of PubMed, as well as trials registers at
ClinicalTrials.gov and the WHO International Clinical Trials Registry
Platform (ICTRP).
Search strategies were designed for maximum sensitivity, to
retrieve all human studies on COVID-19 and with no language limits.
See Appendix 2.
COVID-19 Living Evidence Database from the University of Bern
From 28 March 2020, we used the COVID-19 Living Evidence
database from the Institute of Social and Preventive Medicine
(ISPM) at the University of Bern (www.ispm.unibe.ch), as the
primary source of records for the Cochrane COVID-19 DTA reviews.
This search includes PubMed, Embase, and preprints indexed in
bioRxiv and medRxiv databases. The strategies as described on the
ISPM website are described here (ispmbern.github.io/covid-19/).
See Appendix 3. To ensure comprehensive coverage we also
downloaded records from the ‘Bern feed’ from 1 January to 28
March 2020 and de-duplicated them against those obtained via the
Cochrane COVID-19 Study Register.
The decision to focus primarily on the Bern feed was because of
the exceptionally large numbers of COVID-19 studies available only
as preprints. The Cochrane COVID-19 Study Register has undergone
a number of iterations since the end of March and we anticipate
moving back to the Register as the primary source of records for
subsequent review updates.
Searching other resources
We identified Embase records through the Centers
for Disease Control and Prevention (CDC), Stephen
B Thacker CDC Library, COVID-19 Research
Articles Downloadable Database (www.cdc.gov/library/
researchguides/2019novelcoronavirus/researcharticles.html), and
de-duplicated them against the Cochrane COVID-19 Study Register
up to 28 March 2020. See Appendix 4.
We also checked our search results against two additional
repositories of COVID-19 publications including:
• the Evidence for Policy and Practice Information and Co-
ordinating Centre (EPPI-Centre) 'COVID-19: Living map of the
evidence' (eppi.ioe.ac.uk/COVID19_MAP/covid_map_v4.html);
• the Norwegian Institute of Public Health 'NIPH systematic
and living map on COVID-19 evidence' (www.nornesk.no/
forskningskart/NIPH_diagnosisMap.html)
Both of these repositories allow their contents to be filtered
according to studies potentially relating to diagnosis, and both
have agreed to provide us with updates of new diagnosis studies
added. For this iteration of the review, we examined all diagnosis
studies from either source up to 25 May 2020.
We appeal to researchers to supply details of additional
published or unpublished studies at the following email
address, which we will consider for inclusion in future updates
(coviddta@contacts.bham.ac.uk).
Data collection and analysis
Selection of studies
A team of experienced systematic review authors from the
University of Birmingham screened the titles and abstracts of all
records retrieved from the literature searches. Two review authors
independently screened studies in Covidence. A third, senior review
author resolved any disagreements. We tagged all records selected
as potentially eligible according to the Cochrane COVID-19 DTA
review(s) that they might be eligible for and we then exported them
to separate Covidence reviews for each review title.
We obtained the full texts for all studies flagged as potentially
eligible. Two review authors independently screened the full texts
for one of the COVID-19 biomarker reviews (molecular, antigen or
antibody tests). We resolved any disagreements on study inclusion
through discussion with a third review author.
Data extraction and management
One review author extracted the characteristics of each study,
which a second review author checked. Items that we extracted
are listed in Appendix 5. In addition, we coded tests according
to complexity, regardless of the nature of the test (antigen or
molecular test), as follows:
• low: one sample preparation step and up to two test steps;
• moderate: two sample preparation steps and up to three test
steps;
• high: more than two sample preparation steps and more than
three test steps.
Two review authors independently carried out this classification,
with referral to a third review author if necessary.
Both review authors independently performed data extraction
of 2x2 contingency tables of the number of true positives,
false positives, false negatives and true negatives. They resolved
disagreements by discussion. Where possible, we separately
extracted data according to viral load, and for molecular assays,
before and a-er re-analysis of samples in discrepant cells.
We encourage study authors to contact us regarding missing details
on the included studies (coviddta@contacts.bham.ac.uk).
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Assessment of methodological quality
Two review authors independently assessed risk of bias and
applicability concerns using the QUADAS-2 checklist tailored to this
review (Appendix 6; Whiting 2011). The two review authors resolved
any disagreements by discussion.
Ideally, studies should prospectively recruit a representative
sample of participants presenting with signs and symptoms of
COVID-19, either in community or primary care settings or to
a hospital setting, and they should clearly record the time of
testing a-er the onset of symptoms. Studies in asymptomatic
people at risk of infection should document time from exposure.
Studies should perform tests in their intended use setting, using
appropriate samples with or without viral transport medium and
within the time period following specimen collection as indicated
in the 'instructions for use' document. Tests should be performed
by relevant personnel (e.g. healthcare workers), and should be
interpreted blinded to the final diagnosis (presence or absence of
SARS-CoV-2). The reference standard diagnosis should be blinded
to the result of the rapid test, and should not incorporate the
result of the index test. We did not consider a comparison of
a rapid molecular-based test against an RT-PCR assay to be
at risk of incorporation bias. If the reference standard includes
clinical diagnosis of COVID-19 for RT-PCR-negative patients, then
established criteria should be used. Studies including samples
from participants known not to have COVID-19 should use pre-
pandemic sources or contemporaneous samples with at least one
RT-PCR-negative test result. Data should be reported for all study
participants, including those where the result of the rapid test
was inconclusive, or participants in whom the final diagnosis of
COVID-19 was uncertain. Studies should report whether results
relate to participants (one sample per participant), or samples
(multiple samples per participant).
Statistical analysis and data synthesis
We analysed rapid antigen and molecular tests separately. If studies
evaluated multiple tests in the same samples, we included them
multiple times. We present estimates of sensitivity and specificity
for each test brand using paired forest plots, and summarise results
using average sensitivity and specificity in tables as appropriate.
There were only su&icient studies to make formal comparisons
(based on between-study comparisons) for studies using two
brands of molecular tests (ID NOW (Abbott Laboratories) and Xpert
Xpress (Cepheid Inc)).
We estimated summary sensitivities and specificities with 95%
confidence intervals (CI) using the bivariate model (Reitsma
2005), via the meqrlogit command of Stata/SE 16.0. When few
studies were available, we simplified models by first assuming
no correlation between sensitivity and specificity estimates and
secondly by setting near-zero variance estimates of the random
e&ects to zero (Takwoingi 2017). In cases where there was only one
study per test, we reported individual sensitivities and specificities
with 95% CI constructed using the binomial exact method.
Where studies presented only estimates of sensitivity, we fitted
univariate random e&ects logistic regression models. In a small
number of instances where a model failed to converge (usually
when there were very small numbers of studies or the sensitivity/
specificity estimates were all very high), we computed estimates
and CI by summing the counts of TP, FP, FN and TN across 2x2
tables. These analyses are clearly marked in the tables. We present
all estimates with 95% confidence intervals.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
the forest plots of sensitivity and specificity. Where adequate data
were available, we investigated heterogeneity related to viral load,
test brand, and sample type by including indicator variables in
the random-e&ects logistic regression models. Absolute di&erences
between the sensitivity or specificity and the P values were
reported from the model. In instances where only one study was
available per test or when tests were being directly compared
following summing of counts of the 2x2 tables, we performed test
comparison using the two-sample test of proportions.
Sensitivity analyses
We performed three sensitivity analyses. First, estimation of
sensitivity for molecular tests was made with and without studies
that only evaluated samples with RT-PCR-confirmed SARS-CoV-2
(and thus did not estimate specificity). Secondly, comparisons were
made between analyses using the primary reference standard and
analyses using results adjusted a-er sample retesting with a second
RT-PCR test, either for discrepant cells (discrepant analysis) or for
all samples. Thirdly, we restricted our analysis comparing ID NOW
(Abbott Laboratories) and Xpert Xpress (Cepheid Inc) to studies that
compared the tests in the same samples.
Assessment of reporting bias
We made no formal assessment of reporting bias.
Summary of findings
We summarised key findings in a 'Summary of findings' table
indicating the strength of evidence for each test and findings, and
highlighted important gaps in the evidence.
Updating
We are aware of additional studies published since the search date
of 25 May 2020 and plan to update this review imminently. We have
already completed searches for the update up until 22 June 2020,
and screening of those is ongoing.
R E S U L T S
Results of the search
We screened 19,092 unique records (published or preprints) for
inclusion in the complete suite of reviews to assist in the diagnosis
of COVID-19 (Deeks 2020; McInnes 2020). Of 808 records selected
for further assessment for inclusion in any of the four molecular,
antigen or antibody test reviews, we assessed 90 full-text reports for
inclusion in this review. See Figure 1 for the PRISMA flow diagram
of search and eligibility results (McInnes 2018; Moher 2009). We
included 18 studies from 22 reports in this review, and we excluded
68 publications that did not meet our inclusion criteria. Exclusions
were mainly because of index tests not meeting our criteria for use
at the point of care (n = 36) or ineligible study designs (n = 21).
The reasons for exclusion of all 68 publications are provided in
Characteristics of excluded studies.
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Figure 1.   Study flow diagram
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We contacted the authors of three included studies for further
information (Diao 2020; Porte 2020; Weitzel 2020 [A]), and received
replies and the requested information in regard to all three.
The 22 included study reports relate to 18 separate studies, four
studies having both preprints and subsequent journal publications
(Broder 2020; Mertens 2020; Porte 2020; Smithgall 2020 [A]). Of the
18 studies, five are available only as preprints. (Please note when
naming studies, we use the letters [A], [B], [C] etc. in square brackets
to indicate data on di&erent tests evaluated in the same study).
Description of included studies
The 18 studies include a total of 3198 unique samples, with 1775
samples with RT-PCR-confirmed SARS-CoV-2 (some samples were
analysed by more than one index test). Five studies evaluated
antigen tests (Diao 2020; Lambert-Niclot 2020; Mertens 2020; Porte
2020; Weitzel 2020 [A]) and 13 studies evaluated molecular tests
(Assennato 2020; Broder 2020; Harrington 2020; Hogan 2020;
Lieberman 2020; Loe&elholz 2020; Mitchell 2020; Moore 2020;
Moran 2020; Rhoads 2020; Smithgall 2020 [A]; Wolters 2020; Zhen
2020 [A]). Summary study characteristics are presented in Table
1 with further details of study design and index test details in
Appendix 7 and Appendix 8. Full details are provided in the
Characteristics of included studies table.
The median sample size of the included studies is 112 (interquartile
range (IQR) 96 to 198) and median number of SARS-CoV-2
confirmed samples included is 85 (IQR 50 to 119). The majority of
studies (10/18) were conducted in the USA, four in Europe, two in
South America, one in China and one study included samples from
more than one country.
Participant characteristics
Studies predominantly selected samples from those submitted
to laboratories for routine RT-PCR testing with limited detail of
the participants providing the samples. Three studies included
samples from participants in emergency department or urgent care
settings, three included samples from participants presenting in
mixed settings (inpatient, outpatient or emergency department),
and 12 did not report any details of setting in which study
participants presented.
Four studies included samples from symptomatic patients, only
one of which provided any information on the type of symptoms
experienced and time from symptom onset (median 2 days; IQR 1
to 4; range 0 to 12; Porte 2020). Three additional studies provided
basic demographic data such as age or gender, and the remaining
14 provided no information on participant characteristics.
All five studies evaluating antigen tests reported results for SARS-
CoV-2-confirmed samples with high and low viral load as defined
by the cycle threshold (Ct) value from the reference standard. In
one study (Diao 2020), the proportion with high viral load was 27%
(cut-o& ≤ 30 Ct), and in the other four (using a cut-o& of ≤ 25 Ct) it
ranged from 48% to 74% (Appendix 7). Four studies reporting five
molecular assay evaluations, reported proportions with high viral
load ranging from 33% (Mitchell 2020), to 60% (Smithgall 2020 [A]).
All four studies defined high viral load as Ct of 30 or less. Ct values
were missing for some samples in Porte 2020.
Study designs
We found it di&icult to fully ascertain whether samples were
included in studies with or without knowledge of whether patients
did or did not have COVID-19 infection. All studies defined the
presence or absence of COVID-19 infection based on RT-PCR, with a
single (n = 17) or two (n = 1) negative RT-PCR results used to confirm
the absence of infection. One study used paired nasopharyngeal
swabs for RT-PCR and nasal swabs for the index test (Harrington
2020); all other studies used the same respiratory sample for the RT-
PCR and for the index test.
Nine studies appeared to include series of samples submitted
for laboratory testing regardless of the RT-PCR result, but only
Harrington 2020 reported including consecutive samples, and only
Mertens 2020 randomly selected samples. The number of samples
in these single-group studies ranged from 26 to 524 with between 13
and 208 samples with confirmed SARS-CoV-2 (median prevalence
50%; IQR 41% to 68%).
Seven studies described deliberate separate sampling of RT-PCR-
positive and RT-PCR-negative samples, for example, to ‘enrich’ for
positive samples, to reach a stated ratio of positive to negative
samples, or to represent a range of Ct values on RT-PCR. We
designated these studies as two-group studies. Sample sizes of
these studies ranged from 88 to 481 with between 57 and 220
samples with confirmed SARS-CoV-2 (median prevalence 60%; IQR
46% to 66%).
Two studies included only samples with confirmed SARS-CoV-2,
thus only allowing estimation of sensitivity; 35 samples in Broder
2020, and 96 in Rhoads 2020.
Index tests
Fi-een studies evaluated only one test, three compared two or
more tests using the same samples (two with two tests each, and
one with four tests). In total the 18 studies reported on a total
of 23 test evaluations. Appendix 9 provides details extracted from
the manufacturer’s instructions for use documents for all included
tests.
Antigen tests
Five studies reported eight evaluations of antigen tests (4 CGIA
and 4 FIA), seven of which evaluated one of five commercially
produced tests (produced by Beijing Savant, Shenzhen Bioeasy,
Coris BioConcept, Liming Bio-Products and RapiGEN Inc.) and one
classified as using an in-house CGIA method (full identification
details for all tests is provided in Appendix 8). Contact with the
study author indicates that this study reports the development of
the Shenzhen Bioeasy assay (Diao 2020), but it is not clear whether
the commercially available assay is identical to the one reported in
the study or whether it has undergone further refinement. Only two
studies provided product codes for the tests evaluated (Porte 2020;
Weitzel 2020 [A]; Appendix 8). The Beijing Savant, Coris BioConcept,
Shenzhen Bioeasy and in-house assays all target the nucleocapsid
protein; this information was not reported for the Liming Bio-
Products and RapiGEN Inc.assays (Appendix 8). We have not been
able to identify any information for either the Beijing Savant or
Liming Bio-Products assays online.
Two of the five studies used only nasopharyngeal swab
samples, two used both nasopharyngeal and oropharyngeal
swab samples from all patients (Porte 2020; Weitzel 2020 [A]),
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and one study (Mertens 2020), used mixed swab samples
including nasopharyngeal swabs, nasopharyngeal aspirate and
bronchoalveolar lavage. All studies used samples either in viral
transport medium (n = 4) or in saline solution (n = 1; Diao 2020).
The Coris BioConcept assay, evaluated in two studies (Lambert-
Niclot 2020; Mertens 2020), is the only one to document instructions
for use for swabs in viral transport medium (VTM); the use of
VTM is not mentioned in the instructions for use documents for
any of the other assays (Appendix 9). Samples were tested "soon"
a-er collection in Lambert-Niclot 2020, a-er a defined period of
refrigerated storage in Porte 2020 or frozen storage in Weitzel 2020
[A]; two studies did not report sample storage and timing of testing.
Molecular tests
Thirteen studies reported 15 evaluations of four di&erent
commercially available rapid molecular tests: six evaluating
ID NOW (Abbott Laboratories), seven evaluating Xpert Xpress
(Cepheid Inc), and one evaluation each of Accula (Mesa Biotech Inc.)
and SAMBA II (Diagnostics for the Real World). None of the studies
reported product codes for the tests evaluated (Appendix 8). One
study of Xpert Xpress used the 'research use only' (RUO) version
of the test, but reported that the RUO version contains the same
reagents as the 'emergency use authorisation' (EUA) version. The
RUO test allows the user to view the amplification curves for the
RdRp gene as well as for the E-gene and N2 targets whereas the EUA
version restricts the amplification curves to E and N2 only. ID NOW
and SAMBA-II use isothermal techniques, Xpert Xpress is based on
RT-PCR, and Accula is described as a PCR plus LFA.
In the 13 studies, seven used only nasopharyngeal (n = 6) or
nasal (n = 1) swab samples, one used both nasopharyngeal
and oropharyngeal swab samples from all patients, and the
remaining five evaluations used mixed swab samples including
nasopharyngeal or nasal swabs (n = 3), nasopharyngeal or
oropharyngeal swabs (n = 1), or multiple sample types including
tracheal aspirate (n = 1). One study reported direct swab testing
(Harrington 2020), 10 used either swabs in viral transport medium
(n = 5), viral transport medium or saline (n = 4), or viral transport
medium or gelatin-lactalbumin-yeast (GLY) medium (n = 1), and two
did not report whether any transport medium was used. Five of 13
studies reported testing immediately (n = 1), or within 48 (n = 1) or
72 hours (n = 3) of sample collection. Four studies reported testing
a-er a period of frozen storage, and four did not describe sample
storage or timing of testing at all. Two of the four manufacturers
document instructions for use for samples in transport medium
(for the Xpert Xpress and SAMBA II assays) and two explicitly
recommend against the use of viral transport medium (ID NOW
and Accula), although at the time of the test evaluations, some
viral transport media were documented as acceptable for ID NOW.
Although immediate sample testing is preferred, all manufacturers
document acceptable period of refrigerated storage of between 24
hours (ID NOW) and seven days (Xpert Xpress). See Appendix 9.
Across the 23 test evaluations of antigen or molecular tests, only
one reported testing outside of a centralised laboratory setting,
where direct swab testing (using ID NOW (Abbott Laboratories)) was
carried out by on-site medical personnel or laboratory personnel at
local laboratories (Harrington 2020).
Our own assessment of test complexity across test types classified
SAMBA II as high complexity (more than two sample preparation
steps and more than three test steps), Shenzhen Bioeasy FIA, ID
NOW and Accula as moderate complexity and the other antigen
tests and Xpert Xpress as low complexity (one sample preparation
step and up to two test steps).
Methodological quality of included studies
We report the overall methodological quality assessed using the
QUADAS-2 tool for all included studies (n = 18) in Figure 2 (Whiting
2011). See Appendix 10 for a plot of study-level ratings by quality.
 
Figure 2.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies. Numbers in the bars indicate the number of studies
 
We considered the risk of bias in the individual studies and whether
the results were likely to be applicable to standard use of the tests.
We did not judge any study at low risk of bias and we had concerns
about the applicability of results in all studies. We considered
risk of bias to be high in nine (50%) studies because of how they
selected samples and in 13 (72%) because they considered that one
negative RT-PCR was su&icient to confirm the absence of COVID-19
infection. Lack of details in reporting meant we could not clearly
assess whether there was a risk of bias through performance of the
index test in 11 (61%) studies, or from the way in which the study
was undertaken and analysed in 10 (56%). We judged that there
were high concerns about the applicability of the evidence related
to participants in 13 (72%) studies, to the index test in 13 (72%)
studies and to the reference standard in 17 (94%) studies. We did
not observe di&erences in methodological quality between antigen
and molecular test evaluations. Explanations of how we reached
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these judgements are given below and in the Characteristics of
included studies table.
Participant selection
We judged only two studies to be at low risk of bias, and in
seven (39%) the risk was unclear because of poor reporting. The
remaining 50% (9/18) we judged to be at high risk of bias because
of deliberate sampling of participants based on the reference
standard result; two of which also only included samples with
confirmed COVID-19 infection. We were not able to judge the
appropriateness of study exclusions (16/18) or inclusions (11/18)
where selection was based on the availability of laboratory samples
with no participant eligibility criteria specified. Numbers per group
are not mutually exclusive.
We had high concerns about the applicability of the selected
participants in 13/18 studies (72%), meaning that the participants
who were recruited were unlikely to be similar to those in whom
the test would be used in clinical practice. This was largely because
of the use of deliberate sampling; and sample inclusion based on
the availability of residual and sometimes frozen samples, created
unrepresentative participant samples. We judged only one study
recruiting participants presenting to urgent care or emergency
departments as likely to have selected an appropriate patient
group.
Index tests
Figure 2 demonstrates similar patterns in risk of bias and
applicability of the index test for studies of both antigen and
rapid molecular tests. We observed low risk of bias in four studies
that clearly described interpretation of the index test blinded
to results of the reference standard, and used prespecified test
thresholds. There was high risk of bias in three studies because
the manufacturer’s prespecified threshold for the Xpert Xpress
test (re-testing of samples with presumptive positive results) was
not followed. The risk of bias was unclear in 11 studies because
we could not judge whether interpretation of the index test was
undertaken with knowledge of whether individuals did or did not
have COVID-19 infection.
Thirteen studies did not carry out testing as it would occur in
practice: four studies used trained, centralised laboratory sta& and
not local laboratory or healthcare personnel; one test could not be
purchased (Diao 2020); and 11 because the test was not conducted
within the manufacturer instructions for use (these categories are
not mutually exclusive). Four studies tested samples in a viral
transport medium that was not covered by the manufacturer
instructions for use, five used frozen samples, one reported heat
inactivation of samples prior to direct testing and two reported a
testing timeframe beyond that recommended.
The remaining five studies provided inadequate information to
make a judgement; three of them did conduct the test within
the manufacturer instructions for use but none of them clearly
described the setting for testing or personnel conducting the test.
Reference standards
Only one study used an appropriate reference standard to define
the presence or absence of COVID-19 infection (two negative
PCR results required to confirm the absence of COVID-19) and
implemented it in ways that prevented bias (Diao 2020). One
additional study reported two RT-PCR results for all study
participants (Moore 2020), and two did not include non-COVID-19
cases. We considered that the remaining 14 did not use an adequate
reference standard, putting them at high risk of bias (Figure 2).
Eight studies reported blinded RT-PCR interpretation and 10 (56%)
provided insu&icient information about blinding of the reference
standard to the index test to judge risk of bias.
RT-PCR is unlikely to falsely classify participants as having COVID-19
(low risk of false positive), but may miss true cases leading to false
positives on the index test when a single RT-PCR alone is used as
a reference standard. Four studies (22%) used a second RT-PCR
test for samples with discrepant results (FP and FN) to address
this. However, selective re-testing could miss additional cases of
COVID-19 infection, and is likely to lead to distorted results. One
study (Moore 2020), used a second RT-PCR test in all samples and
furthermore carried out a record review for all cases with discrepant
results in order to verify whether participants were truly considered
to have had COVID-19 infection.
We judged 17 of the 18 studies to raise concerns for applicability
(94%) because of defining the presence of COVID-19 infection based
on a single RT-PCR-positive result. These studies will have excluded
individuals who are RT-PCR-negative but have exposure and clinical
features that meet the case definitions for COVID-19.
Flow and timing
Only three studies were at low risk of bias for participant flow
and timing, one (Porte 2020), used a Standards of Reporting
Diagnostic Accuracy Studies (STARD)-style participant flow diagram
and checklist (Bossuyt 2015), to fully report outcomes for all
samples. Five studies were at high risk of bias because of exclusion
of samples following invalid index test results (they did not carry
out any retesting).
Unclear risk of bias was present in 10 (56%) studies because of
lack of clarity around participant inclusion and exclusion from
analyses. Six studies were unclear regarding whether the analysis
was participant-based or sample-based (where there is a possibility
of multiple samples per participant overstating the precision of
estimates).
Conflicts of interest
In six studies all authors declared no conflicts of interest, although
one study that evaluated an ‘in-house’ test included a co-author
a&iliated to a test manufacturing company. Eight studies did not
provide a conflict of interest statement (one of these included
co-authors a&iliated to the test manufacturer) and in the four
remaining studies at least one author declared conflicts of interest
in relation to the test.
Eleven studies provided no funding statement, five reported no
funding sources to declare, and two reported one or more public
funding sources. Two studies reported receipt of test kits or
reagents ‘in kind’ from test manufacturers.
Findings
Of the 18 included studies, three reported evaluations of more than
one test using the same samples (Table 1). In order to include
all results from all tests in these analyses we have treated results
from di&erent tests of the same samples within a study as separate
data points, such that data are available on 23 test evaluations
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(8 evaluations of antigen tests in 5 studies and 15 evaluations of
rapid molecular tests in 13 studies). The results table (Table 2),
identifies where estimates are based on multiple assessments of
the same samples by including both the number of test evaluations
and the number of studies. The numbers of true positives, false
positives, and total samples with and without confirmed SARS-
CoV-2 infection are based on test result counts.
We undertook analyses separately for antigen tests and for
molecular-based tests. We present results for all analyses in Table
2. Forest plots of study data for the primary analyses are in Figure
3 and Figure 4. Full identification details for all assays are provided
in Appendix 8 and Appendix 9); for brevity, the antigen assays
are referred to by the manufacturer name. Subgroup analyses
according to viral load are in Figure 5 and Figure 6, and rapid
molecular test results before and a-er discrepant analysis are in
Figure 7.
 
Figure 3.   Forest plot of studies evaluating antigen tests. Studies grouped by test




Figure 4.   Forest plot of studies evaluating rapid molecular tests. Studies grouped by test and sample type
(NP: nasopharyngeal; OP: oropharyngeal; RUO: research use only)
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Figure 5.   Forest plot of studies evaluating antigen tests according to viral load: high (≤ 25 Ct) versus low viral load (≤
30 Ct in Diao 2020). Studies grouped by test
 
 
Figure 6.   Forest plot of studies evaluating rapid molecular tests according to viral load: high (≤ 30 Ct) versus low
viral load. Studies grouped by test
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Figure 7.   Forest plot of studies of molecular tests before and aKer discrepant analysis. Studies grouped by test
(DRW: Diagnostics for the Real World; RUO: research use only)
 
Accuracy of antigen tests overall and by test
Average sensitivity across the eight evaluations of antigen tests
was 56.2% (95% CI 29.5 to 79.8%), and average specificity
99.5% (95% CI 98.1% to 99.9%; 943 samples, including 596
samples with confirmed SARS-CoV-2; Table 2). However, Figure
3 shows considerable heterogeneity in sensitivity, with results
across studies ranging from 0% to 94%. The average value should
therefore be interpreted with caution as there may be real
di&erences in sensitivity between the test brands. The two assays
with lowest sensitivity (Liming Bio-Products and Beijing Savant
assays) do not now appear to be commercially available. Pooled
results for the two tests with two studies each suggested higher
sensitivity for the Shenzhen Bioeasy FIA (89.5%, 95% CI 83.7% to
93.8%) than the Coris BioConcept CGIA (54.4%, 95% CI 47.7% to
61.0%), but these tests were not evaluated in the same studies
and other factors may explain the observed di&erences. Similar,
unknown factors may explain di&erences between the Shenzhen
Bioeasy and Coris BioConcept assays and the other tests for which
only single studies were available. Specificities were consistent and
high, with point estimates of 99% or 100% in seven evaluations, and
one study estimating specificity as 90% but with a 95% confidence
interval that included 100%.
Accuracy of rapid molecular tests overall and by test
Average sensitivity and specificity for the 13 rapid molecular test
evaluations that included samples with and without SARS-CoV-2,
were 95.2% (95% CI 86.7% to 98.3%) and 98.9% (95% CI 97.3% to
99.5%; 2255 samples, 1179 with confirmed SARS-CoV-2). Adding
the two 'cases only' studies made little di&erence to the average
sensitivity (95.5%, 95% CI 88.5% to 98.4%; 1244 cases). We excluded
these two studies from further analyses (Broder 2020; Rhoads
2020).
Figure 4 demonstrates heterogeneity in sensitivity estimates
(ranging from 68% to 100%), with consistently high specificities
(92% to 100%, but with upper limits of 95% CIs of 99% or 100% in
every study). Of the four di&erent molecular tests evaluated, two
were evaluated in one study each. The sensitivity and specificity of
the Accula test were 68.0% (95% CI 53.3% to 80.5%) and 100% (95%
CI 92.9% to 100%; 100 samples, 50 with confirmed SARS-CoV-2). For
SAMBA II, sensitivity and specificity were 98.9% (95% CI 93.8% to
100%) and 96.4% (95% CI 89.9% to 99.3%; 172 samples, 88 with
confirmed SARS-CoV-2).
The ID NOW and Xpert Xpress tests were evaluated in five studies
(1003 samples, 496 with confirmed SARS-CoV-2) and six studies (919
samples, 479 with confirmed SARS-CoV-2), respectively. Pooled
analysis showed the Xpert Xpress test to have higher sensitivity
(99.4%, 95% CI 98.0% to 99.8%) in comparison to ID NOW (76.8%,
95% CI 72.9% to 80.3%), a di&erence of 22.6 (95% CI 18.8 to 26.3)
percentage points (Table 2). Whilst the specificity of Xpert Xpress
(96.8%, 95% CI 90.6 % to 99.0%) was marginally lower than ID-NOW
(99.6%, 95% CI 98.4% to 99.9%) the di&erence was of a magnitude
that can be explained by chance (di&erence of −2.8, 95% CI −6.4
to 0.8) percentage points (P = 0.13)). Restricting the analysis to the
two studies that compared the two tests in the same patients gave
very similar results (di&erence in sensitivity of 19.3% (95% CI 12.5%
to 26.2%) and di&erence in specificity of −2.7 percentage points
(95% CI −6.3 to 1.0), based on 221 samples, 146 with SARS-CoV-2;
Smithgall 2020 [A]; Zhen 2020 [A])). (This analysis used the two-
sample test of proportions).
Subgroup analyses by sample type
Adequate data for di&erent sample types were available for studies
using nasopharyngeal samples only. We observed similar average
sensitivity (59.4%, 95% CI 50.7% to 67.5%) and specificity (99.6%,
95% CI 97.4% to 99.9%) for three evaluations of antigen tests (705
samples, 434 with confirmed SARS-CoV-2). For six evaluations of
molecular tests, average sensitivity appeared lower compared to
the overall pooled estimate (87.1%, 95% CI 71.6% to 94.7%) with
little change in specificity (Table 2).
Subgroup analyses by viral load
We extracted sensitivity data according to viral load from seven
evaluations of antigen tests (three with the assistance of the study
authors) and five evaluations of molecular tests. Ct threshold for
high viral load was 25 or less for four of the five antigen studies
and 30 or less for the remaining antigen evaluation and for all of
the molecular assay evaluations. We observed a large di&erence
in sensitivity in the high viral load group (400 with confirmed
SARS-CoV-2) for antigen tests (di&erence of 60.6 percentage points
(95% CI 38.2, 83.0) compared to low viral load (341 samples with
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confirmed SARS-CoV-2) that was beyond that expected by chance
(P < 0.001) (Table 2; Figure 5).
For molecular tests, all sensitivity estimates for the high viral load
subgroups were 100% (based on 151 samples with confirmed
SARS-CoV-2) compared to between 34% and 100% for low viral
load subgroups (summary sensitivity 93.3%, 95% CI 46.7% to
99.6%; 142 samples with confirmed SARS-CoV-2; Table 2; Figure
6). The evaluations with the lowest sensitivities both evaluated ID
NOW, with reported sensitivity estimates of 34% (35 samples with
confirmed SARS-CoV-2 in Smithgall 2020 [A]), and 58% (based on 31
samples with confirmed SARS-CoV-2 in Mitchell 2020). Sensitivity
in the three evaluations of Xpert Xpress ranged from 97% (35
samples with confirmed SARS-CoV-2 in Smithgall 2020 [B]) to 100%
(in Lieberman 2020 and Wolters 2020, with 7 and 34 samples with
confirmed SARS-CoV-2 respectively).
Sensitivity analysis of the impact of discrepant analysis
Four evaluations of molecular tests (in 1566 samples) reported
results before and a-er discrepant analysis where selected samples
were re-tested with either the same (Harrington 2020; Moran 2020),
or an alternative RT-PCR assay (Assennato 2020; Loe&elholz 2020),
three of which also reported re-testing of samples with the index
test (Assennato 2020; Harrington 2020; Moran 2020; Table 3; Figure
7).
Discrepant analysis always works to reduce the number of samples
deemed to be false negative or false positive errors. Discrepant
analysis reduced the false negative proportion (1-sensitivity) from
1.8% to 0.5% and the false positive rate (1-specificity) from 2.2%
to 0.4%. Three of the four studies reporting initially ‘false positive’
results reported zero false positives a-er sample re-testing and one
reported a drop in false positives from 11 to 3 (Loe&elholz 2020;
Table 3). One of the two studies reporting re-testing of initially
‘false negative’ results reported reclassification as true negative
on re-testing, and in the other the false negative remained as a
false negative. Given the bias inherent in choosing the reference
test dependent on the observed results, we caution against these
findings.
An additional study tested all samples with two di&erent RT-
PCR assays, and hence used a more accurate reference standard
in all samples, not just samples with discrepant results (Moore
2020), in which six initial true negatives were reclassified as
false negatives a-er the second RT-PCR. Had discrepant analysis
been undertaken these misclassifications would have been
missed, further underlining the methodological flaws inherent to
discrepant analysis.
Other sources of heterogeneity
We planned to evaluate the e&ect of other sources of heterogeneity,
including study design, reference standard, length and severity of
symptoms, and setting. However, additional formal investigations
using meta-regression were not possible because of limited data,
lack of reporting or lack of variability across the studies in these
features (Appendix 11). Only one study reported the median time
to testing a-er symptom onset, none reported symptom severity,
and three reported the setting in which tests were conducted. All
studies used RT-PCR alone as the reference standard for diagnosing
COVID-19 infection.
We anticipate revisiting the e&ect of study design and including a
more detailed investigation by sample type in future iterations of
this review.
D I S C U S S I O N
This is the first version of a Cochrane living review summarising the
accuracy of point-of-care antigen and molecular tests for detecting
current SARS-CoV-2 infection. This version of the review is based
on published studies, or studies available as preprints, up until 25
May 2020. We are continually identifying new published studies,
and plan regular updates of this review.
Summary of main results
We included data from 18 studies including 3198 samples
(including 1775 samples with confirmed SARS-CoV-2). Five studies,
reporting eight test evaluations, considered antigen tests and 13
studies, reporting 15 test evaluations, considered rapid molecular
tests. Key findings are presented in the Summary of findings 1.
We summarise five key findings from this review.
1. A significant proportion of antigen and molecular assays that are
suitable for use at the point of care do not have any published
or preprint reports of accuracy. This review has evaluated data
from five commercial antigen tests, two of which we could not
identify as available for purchase, and four molecular assays.
These represent a small proportion of assays currently available.
We have identified 24 additional studies of rapid antigen or
molecular tests published or available as preprints up until 22
June 2020, which we will appraise for inclusion in the review
update, but there still remain no published data for the majority
of tests on the current FIND list.
2. The design and execution of studies limits the strength of
conclusions that we are currently able to draw, either for antigen
or for molecular tests. It is unclear whether the limitations in
the primary studies will lead to over- or under-estimates of
test accuracy, thus all results we report should be interpreted
with a high degree of caution. Half of studies used deliberate
sampling based on the presence or absence of confirmed
COVID-19 infection, and the majority selected samples from
those submitted to laboratories for routine RT-PCR testing with
little to no detail of the participants who provided the samples in
relation to either symptom status or time from symptom onset.
It is impossible to determine the e&ect of inclusion decisions
based on the availability of residual or remnant samples. It
was not always clear how many samples were included from
each participant, and the analysis had to be undertaken on a
per-sample basis, which will have overestimated the precision
of the estimates. RT-PCR was the only reference standard for
diagnosing the presence of SARS-COV-2 infection so that we are
unable to comment on the accuracy of rapid tests for diagnosing
infection in those who are RT-PCR negative but meet case
definition criteria for the presence of infection. The use of a
second RT-PCR assay to determine the disease status of samples
with discrepant results following rapid molecular testing is likely
to introduce further bias.
3. Three-quarters of studies conducted tests outside of
manufacturers’ instructions for use, particularly in regard to
sample storage and use of transport media, and with tests
conducted in centralised laboratories rather than at the point
of care, so that test accuracy in a clinical setting remains
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unknown. We considered five tests, including one molecular
assay, to have low complexity in terms of minimal sample
preparation and test steps, and the other four to have moderate
(n = 3) or high (n = 1) complexity, which could also a&ect
how well the observed accuracy translates into practice. We
did not include interpretation steps in our assessment of test
complexity; however the use of reader devices, for example for
FIAs, could be considered to further add to complexity.
4. On average, the sensitivity of antigen tests was relatively poor
(56.2%, 95% CI 29.5 to 79.8%), but with consistently high
specificities (average 99.5%, 95% CI 98.1 to 99.9%). However,
there is considerable heterogeneity in sensitivities between
studies, and with limited data for individual tests. We observed
large di&erences in sensitivity according to viral load and
suspect that di&erences in the distribution of samples with high
and low viral load between studies may have a&ected overall
accuracy estimates. Combined with methodological limitations
and other unknown factors, it is not possible to state with any
certainty whether any test is superior to the others. There is a
suggestion of higher sensitivity in two studies of the Shenzhen
Bioeasy fluorescent immunoassay (sensitivity 89.5%, 95% CI
83.8%, 93.3%), that was maintained in subgroup analysis by
viral load (one of the two obtained over 90% of samples during
the first week of symptoms). An additional study reporting the
development of this assay reported lower sensitivity overall
(68%, 95% CI 61, 74%), however it included a much lower
proportion of samples with high viral load (27% compared to 68
to 74% in the other two studies). Subgroup analysis suggested
the test performed similarly to the other two studies when
restricted to high and low viral load subgroups. All three studies
included high percentages of samples with confirmed SARS-
CoV-2, and more data is needed to determine whether test
performance for this assay can be repeated in clinical practice.
5. On average, the sensitivity for the rapid molecular tests was
95.2% (95%CI 86.7%, 98.3%) with specificity 98.9% (95% CI 97.3,
99.5%). Although the average estimates are based on twice as
much data as for the antigen tests, the evaluations are subject
to the same methodological limitations, and we do not know
how the assays would perform in any specific clinical setting
when used in people suspected of having COVID-19 infection or
of having been exposed to a confirmed case.
Most of the evaluations of molecular tests were of ID NOW or
Xpert Xpress. Summary sensitivity for Xpert Xpress (99.4%, 95% CI
98.0 to 99.8%) was 22.6 percentage points higher than that of ID
NOW, a magnitude of di&erence that was more or less maintained
in the two direct comparisons of the two assays. Concerns over
risk of bias would suggest that this high rate of sensitivity
might be an over-estimate. However as both sets of studies have
similar methodological limitations, it is probably reasonable to
presume that some di&erence in sensitivity between tests would be
maintained if these sources of bias were removed. The di&erence
in specificity between the tests is small (ID NOW being 2.8%
more specific compared to Xpert Xpress), but potentially important
especially if used in a low-prevalence setting. However, this would
not be an issue should test positives be confirmed by a laboratory-
based RT-PCR assay. Concerns about the applicability of study
participants and index tests brings into question whether similar
di&erences in test performance would be observed in practice.
As stated above, we did not undertake a formal comparison
between antigen and molecular assays because of the lack of
direct head-to-head comparisons of the two test types. However,
the possible e&ect of the observed di&erences in accuracy can be
illustrated by applying the summary estimates of test accuracy
to a hypothetical cohort of 1000 people suspected of COVID-19
infection (Summary of findings 1). If 100 people had confirmed
SARS-COV-2 infection (prevalence of 10%), the average sensitivity
and specificities of antigen tests mean that 5 of 61 people with
a positive test result would be false positives (positive predictive
value (PPV) 92%) while 44 of 940 people with negative test results
would be falsely negative (negative predictive value (NPV) 95%). As
there is high heterogeneity in the estimates of sensitivity, the values
observed in practice could vary considerably from these figures. For
molecular assays at the same prevalence, 10 of 105 positive test
results would be false positive (PPV 90%), and 5 of 895 with negative
results would be falsely negative (NPV 99%).
Small decreases (to 5%) or increases (to 20%) in prevalence make
little di&erence to the absolute number of false positive results,
but have a large relative e&ect when considered in relation to
the number of positive test results (PPV ranging 85% to 97% for
antigen tests and 83% to 95% for molecular assays). The NPV
(percentage of negative test results that are truly negative) for
the molecular assays is not a&ected by these prevalence changes
in the same way because of the relatively high sensitivity and
relatively low-prevalence scenarios considered. Wider variation is
observed for antigen tests (98% to 90%). This shows how even
in a low-prevalence setting, tests with poor sensitivity can have a
considerable impact on the level of confidence that can be had in
a negative test result. However, we emphasise that these numbers
are not based on any evidence comparing antigen and molecular
tests in the same samples.
We saw a similar pattern of results when applying summary results
for individual tests with wide variations in sensitivity and only small
di&erences in specificities (Summary of findings 1).
Strengths and weaknesses of the review
Our review used a broad search screening all articles concerning
COVID-19. We undertook all screening and eligibility assessments,
QUADAS-2 assessments (Whiting 2011), and data extraction of
study findings independently and in duplicate. Whilst we have
reasonable confidence in the completeness and accuracy of the
findings up until the search date, should errors be noted please
inform us at coviddta@contacts.bham.ac.uk so that we can check
and correct in our next update.
We identified one other systematic review of point-of-care tests
for detection of SARS-CoV-2 that is currently available only as a
preprint (Subsoontorn 2020). The review did not consider antigen
tests or RT-PCR-based tests (such as Xpert Xpress), instead focusing
on molecular tests that do not require the use of a thermal cycler.
We undertook a careful assessment of test complexity to ensure
that included tests were suitable for use at the point of care. This
assessment included explicit consideration of sample preparation
and biosafety requirements as well as time to test result. The
application of these index test criteria led to the exclusion of
the majority of the 31 RT-LAMP or CRISPr assay evaluations that
were included in Subsoontorn 2020. Evaluations of alternative
laboratory-based molecular technologies are under consideration
for inclusion in another review in our series of Cochrane COVID-19
DTA reviews. An additional seven studies included in Subsoontorn
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2020 became available a-er our search cut-o& and are already
under consideration for inclusion in the review update.
Weaknesses of the review primarily reflect the weaknesses in
the primary studies and their reporting. Many studies omitted
descriptions of participants, and key aspects of study design and
execution. In order to include data for all tests in pooled analyses
we have had to include some samples multiple times. We have
been explicit about these issues where they arose. It is possible that
eligible studies have been missed by our search strategy however
we believe the risk to be very low considering our broad approach
to identification of literature.
Around a quarter (5/18) of the studies we have included are
currently only available as preprints, and as yet, have not
undergone peer review. As published versions of these studies are
identified in the future, we will double-check study descriptions,
methods and findings, and update the review as required.
Applicability of findings to the review question
We have concerns about the applicability of the evidence that we
have identified for point-of-care tests.
Due to lack of reporting, we do not know whether tests perform
in the same way or di&erently according to whether those being
tested have symptoms of COVID-19, and if so how long they
have experienced those symptoms for, or are asymptomatic.
Studies appeared to include remnant or residual samples for
testing and many selectively included high percentages of samples
with RT-PCR-confirmed SARS-CoV-2. In reality, point-of-care tests
will be considered for use in much lower prevalence settings.
Methodological work on diagnostic test evaluations has shown
that independently of prevalence, tests do not necessarily exhibit
the same sensitivity and specificity in di&erent prevalence settings
(Usher-Smith 2016). This can be because of di&erences in the
case-mix or ‘spectrum’ of disease (e.g. viral load). However, the
mechanisms in action can be complex and di&icult to clearly
identify (Leeflang 2013).
We also had concerns about the way in which many of the tests
evaluated were performed outside of manufacturer instructions for
use, and not in fact at the point of care.
Great caution should be taken in applying these results outside of
the individual study contexts.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In the Role of index test(s) section, we suggested two main roles for
point-of-care testing.
1. As a replacement for laboratory-based RT-PCR, if su&iciently
accurate. Evidence included to date suggests that some rapid
molecular tests might have accuracy levels approximating those
of laboratory-based RT-PCR. However, many of the data come
from two-group studies with deliberate over-sampling of cases
and concerns over the applicability of the evidence. We cannot
be certain as to whether any test performs su&iciently well for
this role.
2. As a triage to RT-PCR, allowing earlier detection and
rapid management (self-isolation, quarantine or therapeutic
intervention) of those testing positive; those with negative
results waiting for the laboratory-based RT-PCR result. On
current evidence of test performance (using average observed
sensitivities and specificities), rapid tests could only perform
this type of triage role in higher-prevalence settings (i.e. 20%
or higher) because of the (relative) risk of false positive results
in lower-prevalence settings. Although average test specificities
are high for both antigen and for molecular tests, unnecessary
quarantine measures for 1 in 6 (83% PPV), or even 1 in 10
(90% PPV), people with a positive test result would seem a
relatively high price to pay for a rapid result. The 99% to
100% specificities observed for individual tests would need
to be replicated in well designed field studies, and following
manufacturers’ instructions for use, before any test could be
recommended for use as a triage test.
Alternatively, serial testing (over a number of days), or
combinations of di&erent rapid tests (e.g. an antigen test followed
by a rapid molecular test) on the same sample may provide a useful
testing strategy; however, additional evidence of the performance
of any such diagnostic strategy would be needed. In the absence of
further evidence, and in low prevalence settings, both positive and
negative results from any of the rapid point-of-care tests included in
this review would need to be followed up with a laboratory-based
RT-PCR.
Ultimately, decisions around rapid testing will be driven not only
by diagnostic accuracy but by acceptable levels of test complexity,
time to result, and acceptability to those being tested, all of which
might vary according to the setting in which the tests are to be used.
In settings where RT-PCR is not available, rapid tests may have a
role if accpetable performance targets for diagnostic test accuracy,
such as those laid out in WHO's priority target product profiles for
COVID-19 diagnostics, can be met (WHO 2020c).
Implications for research
A considerable volume of research has already emerged for point-
of-care tests for COVID-19 infection. However further prospective
and comparative evaluations of individual tests, either alone or
in combination, and in clinically relevant settings are urgently
needed. These settings include those where people with signs and
symptoms present for testing as well as those involving testing
asymptomatic people who may have come into contact with
confirmed cases. Reliable and ideally rapid diagnostic tests are
the keystone to good track and trace programmes, as a means of
implementing necessary self-isolation or quarantine and reducing
community transmission. Studies should recruit consecutive series
of eligible participants and should clearly describe symptomatic
status, and should document time from symptom onset or
time since exposure. Point-of-care tests must be conducted in
accordance with manufacturer instructions for use, and across the
spectrum of point-of-care settings and test operators.
We observed a number of studies of molecular assays employing
discrepant analysis to confirm the disease status of samples with
false positive results in particular. There is a considerable risk
of this type of selective re-testing leading to distorted results. If
there is su&icient concern about the reliability of a single RT-PCR
test then all samples should be tested with two RT-PCR assays.
Finally, any future research study needs to be clear about eligibility
and exclusion decisions throughout the whole diagnostic pathway,
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and should conform to the updated Standards for Reporting of
Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Single-group study to estimate sensitivity and specificity:
- samples from symptomatic individuals with suspected COVID-19 sent for routine labo-
ratory diagnosis; supplied via PHE (n = 172)
Recruitment: not stated
Assennato 2020 
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Prospective or retrospective: retrospective
Number of samples (samples with confirmed SARS-CoV-2): 172 (88)
Patient characteristics and setting Setting: not stated; supplied by PHE
Location: PHE, Cambridge Laboratory (samples from East of England)
Country: UK
Dates: not stated
Symptoms and severity: symptomatic; no further details
Demographics: not stated
Exposure history: not stated
Index tests Test name: SAMBA II SARS-CoV-2 Test
Manufacturer: Diagnostics for the Real World
Antigen target: ORF1ab, N2
Antibody: N/A
Test method: rapid PCR
Samples used: combined nose and throat swab samples, provided as VTM
Transport media: samples diluted 1:2 with SAMBA SCoV bu&er
Sample storage: not stated
Test operator: not stated; presume laboratory sta&
Definition of test positivity: as per manufacturer; either target present
Blinding reported: yes; states that samples were rendered anonymous and provided
blinded for the purpose of test validation
Timing of samples: not stated
Target condition and reference stan-
dard(s)
Reference standard: RT-PCR; (1) Cambridge RdRp gene (Wuhan) assay on the Rotor gene
Q real-time PCR assay routinely used by PHE; Ct ≤ 36 considered positive. (2) Samples al-
so tested with the PHE Colindale (Reference Laboratory) assay
Definition of non-COVID cases: Single RT-PCR negative
Genetic target(s): (1) RdRp, E gene, (2) RdRp 'different region'
Samples used: combined nose and throat swab in VTM; same as for index test
Timing of reference standard: not stated; Cambridge assay seems to have been part of
routine testing near to time of sample collection; not clear if Colindale assay was at a
later date after a period of storage
Blinded to index test: not stated but seems yes for Cambridge assay
Incorporated index test: no
Flow and timing Time interval between index and reference tests: not stated; seems likely reference was
carried out for routine diagnostic testing
All participants received same reference standard: yes (all samples underwent both RT-
PCR tests)
Assennato 2020  (Continued)
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Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): 3 FP and 1 FN result retested using SAMBA-II; same re-
sults obtained on repeat
Indeterminate results (reference standard): 3 FP and 1 FN result were re-tested
- all 3 FPS found to be borderline positive for ≥ 1 target gene on either Colindale or Cam-
bridge (Wuhan) test (reclassified as TP)
- the FN result remained positive on both RT-PCR assays
Unit of analysis: refers to participants rather than samples
Comparative  




Author COI: no COI statement reported; 3 co-authors are affiliated to test manufacturer
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Unclear    
Did the study avoid inappropriate inclu-
sions?
Unclear    
Could the selection of patients have in-
troduced bias?
  Unclear risk  
Are there concerns that the included
patients and setting do not match the
review question?
    Unclear
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Yes    
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Could the conduct or interpretation of
the index test have introduced bias?
  Low risk  
Are there concerns that the index test,
its conduct, or interpretation differ
from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
No    
Were the reference standard results inter-
preted without knowledge of the results
of the index tests?
Yes    
Reference standard does not incorporate
result of index test?
Yes    
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
  High risk  
Are there concerns that the target con-
dition as defined by the reference stan-
dard does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference standard?
Yes    
Did all patients receive the same refer-
ence standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference
standard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling Single-group study to estimate sensitivity:
- samples positive on Roche cobas 6800 assay in lower range of viral load (E tar-
get Ct ≥ 30) (n = 35)
Recruitment: not stated; deliberate sampling according to viral load
Prospective or retrospective: unclear
Broder 2020 
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Number of samples (samples with confirmed SARS-CoV-2): 35 (35)
Patient characteristics and setting Setting: not stated




Symptoms and severity: not stated; lower viral load
Demographics: not stated
Exposure history: not stated
Index tests Test name: GeneXpert Xpress SARS-CoV-2 assay (no product code reported)
Manufacturer: Cepheid
Antigen target: not stated E gene
Antibody: N/A
Test method: rapid PCR
Samples used: NP swabs in VTM
Transport media: not stated
Sample storage: within 3 days of initial testing (with RT-PCR)
Test operator: not stated; presume laboratory sta&
Definition of test positivity: not stated; “all specimens were tested using the
manufacturer’s protocol”, no mention of presumptive positives
Blinding reported: not stated
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: Roche cobas 6800 SARS-CoV-2 assay
Definition of non-COVID cases: N/A
Genetic target(s): E gene (unclear if other genetic targets as well)
Samples used: NP swabs (as for index test)
Timing of reference standard: not stated; presume on presentation
Blinded to index test: not stated; presume yes
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same samples; index within 3
days of reference
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): none reported
Broder 2020  (Continued)
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Indeterminate results (reference standard): discrepancies resolved using modi-
fied CDC RT-PCR; 1 FN confirmed as disease negative (i.e. a TN)
Unit of analysis: not stated; refers only to samples
Comparative  
Notes Funding: no funding described
Publication status: accepted manuscript
Source: Journal of Clinical Microbiology
Author COI: Dr. Kra- participated on a Roche advisory board regarding COVID
serology. All other study authors have no conflicts
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have introduced
bias?
  High risk  
Are there concerns that the included patients
and setting do not match the review question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the in-
dex test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its con-
duct, or interpretation differ from the review
question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
Yes    
Broder 2020  (Continued)
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)










Cochrane Database of Systematic Reviews
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Unclear    
Reference standard does not incorporate result of
index test?
Yes    
Could the reference standard, its conduct, or
its interpretation have introduced bias?
  Unclear risk  
Are there concerns that the target condition
as defined by the reference standard does not
match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference standard? Yes    
Were results presented per patient? Unclear    





Patient Sampling Single group estimating sensitivity and specificity for detecting active disease
- samples from cases of suspected SARS-CoV-2 infection (n = 239)
Recruitment: not stated if participants were consecutive
Prospective or retrospective: retrospective
Number of samples (samples with confirmed SARS-CoV-2): 239 (208)
Patient characteristics and setting Setting: hospital (inpatients)
Location: 7 centres, including General Hospital of Central Theatre Command, Wuhan
No.7 People’s Hospital, Wuhan Pulmonary Hospital, Hubei Maternal and Child Hos-
pital, Taikang Hospital, Hanyang Hospital and Wuguo Hospital. Urine study done in
Southwest Hospital in Chongqing
Country: China
Dates: not stated
Symptoms and severity: not stated
Demographics: not stated
Diao 2020 
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Exposure history: not stated
Index tests Test name: not stated
Manufacturer: in house (but study authors affiliated to Bioeasy Technology)
Antibody: monoclonal antibody
Antigen target: nucleocapsid protein (N-antigen)
Test method: FIA (fluorescence immunochromatographic); requires immunofluores-
cence analyser
Samples used: NP (all), urine (subgroup)
Transport media: samples diluted and mixed in 500 μL saline solution; 100 μL trans-
ferred to the sample well of the test card
Sample storage: not reported
Test operator: not stated; presume laboratory sta&
Definition of test positivity: cut-o& value was determined by testing 100 nasal swab
samples of healthy people and calculated as the mean value of the fluorescence sig-
nal plus 5 SD.
Blinding reported: done in parallel; blinded
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: RT-PCR (Daan Gene kit); performed on ABI Prism 7500 and Light
Cycler 480 real-time PCR system. Threshold < 40 Ct; threshold < 30 Ct also investigat-
ed
Definition of non-COVID cases: all participants underwent 3 nucleic acid tests, and the
results of each nucleic acid test were verified by 2 COVID-19 nucleic acid test kits.
Genetic target(s): ORF1ab and N gene
Samples used: NP swab, same as for index test
Timing of reference standard: not stated
Blinded to index test: done in parallel; blinded
Incorporated index test: no
Flow and timing Time interval between index and reference tests: done in parallel
All participants received same reference standard: yes
Missing data: not reported
Uninterpretable results: not reported
Indeterminate results (index test): none reported
Indeterminate results (reference standard): none described
Unit of analysis: participants
Comparative  
Notes Funding: this research was supported by grants from National Key R&D Program
of China (2016YFA0502204); Chongqing Health Commission COVID-19 Project
(2020ZX01).
Diao 2020  (Continued)
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Publication status: preprint (not peer-reviewed)
Source: medRxiv preprint
Author COI: study authors declare no COI present; 1 affiliated to Shenzhen Bioeasy
Biotechnology Co. Ltd.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Unclear    
Did the study avoid inappropriate inclu-
sions?
Unclear    
Could the selection of patients have intro-
duced bias?
  Unclear risk  
Are there concerns that the included pa-
tients and setting do not match the re-
view question?
    Unclear
DOMAIN 2: Index Test (Antigen tests)
Were the index test results interpreted with-
out knowledge of the results of the refer-
ence standard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the
index test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    High
DOMAIN 2: Index Test (Rapid PCR tests)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Yes    
Were the reference standard results inter-
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Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced
bias?
  Low risk  
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling Single-group study to estimate sensitivity and specificity:
- symptomatic patients meeting diagnostic criteria for COVID-19 (n = 524)
Recruitment: consecutive
Prospective or retrospective: unclear; presume prospective
Number of samples (samples with confirmed SARS-CoV-2): 524 (186)
Patient characteristics and setting Setting: ED (n = 3) or urgent (immediate) care centres (n = 2)




Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: ID NOW COVID-19 assay (no product code provided)
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Manufacturer: Abbott
Antigen target: not stated
Antibody: N/A
Test method: not stated; isothermal PCR
Samples used: nasal swabs (provider collected)
Transport media: none; direct testing after heat inactivation
Sample storage: ED swabs transported in sterile transport containers (using cups or
conical tubes)
Test operator: on-site medical personnel (urgent care centres); laboratory personnel at
each separate location (EDs)
- 2 sites reportedly experienced users of ID NOW (one ED and one urgent care centre)
and 3 sites received training)
Definition of test positivity: as per manufacturer
Blinding reported: yes (RT-PCR performed at separate central lab)
Timing of samples: not stated; on presentation
Target condition and reference standard(s) Reference standard: RT-PCR (Abbott RealTime SARS-CoV-2 (ACOV) assay performed on
the Abbott m2000 system (Abbott Molecular Inc. Des Plaines, IL); threshold not stated
Definition of non-COVID cases: not specifically stated; presume yes as central lab used
Genetic target(s): not stated
Samples used: NP swabs
Timing of reference standard: VTM (no detail)
Blinded to index test: not stated, transferred to central clinical laboratory; samples
heat inactivated for 30 min at 60 °C prior to testing
Incorporated index test: no (paired collection with swabs for index test)
Flow and timing Time interval between index and reference tests: simultaneous swab collection (differ-
ent swabs for index and reference)
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): none reported
Indeterminate results (reference standard): 2 initial FPs had repeat sampling:
- 1 retested on RT-PCR only and was positive (designated as TP)
- 1 retested on RT-PCR and ID NOW and was negative on both (designated as FP based
on original sampling)
Unit of analysis: participants
Comparative  
Notes Funding: study authors received "received no specific grant from any funding agency in
the public, commercial, or not-for-profit sectors"
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Publication status: accepted manuscript
Source: Journal of Clinical Microbiology
Author COI: COI not mentioned
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Yes    
Did the study avoid inappropriate inclu-
sions?
Yes    
Could the selection of patients have in-
troduced bias?
  Low risk  
Are there concerns that the included pa-
tients and setting do not match the re-
view question?
    Low concern
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted
without knowledge of the results of the ref-
erence standard?
Yes    
If a threshold was used, was it pre-speci-
fied?
Yes    
Could the conduct or interpretation of
the index test have introduced bias?
  Low risk  
Are there concerns that the index test,
its conduct, or interpretation differ from
the review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correct-
ly classify the target condition?
No    
Were the reference standard results inter-
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Reference standard does not incorporate
result of index test?
Yes    
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
  High risk  
Are there concerns that the target con-
dition as defined by the reference stan-
dard does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
Did all participants receive a reference
standard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling Single-group design to estimate sensitivity and specificity
- samples from adult patients from 1 hospital and paediatric and adult samples
from surrounding hospitals
Recruitment: unclear; equal numbers of positive and negative RT-PCR samples (sus-
pect deliberate sampling by PCR result)
Prospective or retrospective: not stated
Number of samples (samples with confirmed SARS-CoV-2): 100 (50)
Patient characteristics and setting Setting: hospital; not stated if inpatient or outpatient (samples selected from clini-
cal virology laboratory)
Location: Stanford Health Care (hospital), and surrounding hospitals (not named)
Country: USA
Dates: 7-13 April 2020
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
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Index tests Test name: Accula SARS-CoV-2 POCT (no product code reported)
Manufacturer: Mesa Biotech, Inc., San Diego, CA
Antigen target: N gene
Antibody: N/A
Test method: rapid PCR
Samples used: NP swabs in VTM (n = 37) or saline (n = 63, including 37 positive on
RT-PCR)
Transport media: not stated; 10 μL of VTM or saline was transferred to 60 μL of
SARS-CoV-2 bu&er within a biosafety cabinet (not covered by manufacturer IFU)
Sample storage: not stated; testing appears to have been conducted soon after
sample collection
Test operator: not stated; presume laboratory sta&
Definition of test positivity: as per manufacturer
Blinding reported: not stated
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: RT-PCR; in-house SHC assay (cites Hogan 2020 10.1016/
j.jcv.2020.104383:104383)
Definition of non-COVID cases: single RT-PCR negative
Genetic target(s): E gene
Samples used: NP swabs, same as for index test
Timing of reference standard: not stated
Blinded to index test: not stated
Incorporated index test: no
Flow and timing Time interval between index and reference tests: not stated but implies that both
tests undertaken in laboratory soon after sample collection
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: 3 invalid results were re-tested; 1 positive and 2 negative
Indeterminate results (index test): 1 known RT-PCR-positive sample that showed a
faint positive test line was re-tested and again showed the same faint test line (con-
sidered positive)
Indeterminate results (reference standard): none reported
Unit of analysis: refers to participants
Comparative  
Notes Funding: study authors report no specific funding
Publication status: preprint
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Source: medRxiv
Author COI: authors declare no COI present
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have intro-
duced bias?
  Unclear risk  
Are there concerns that the included pa-
tients and setting do not match the review
question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the
index test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Unclear    
Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced bias?
  High risk  
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Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling Single-group study to estimate sensitivity and specificity:
- samples submitted for RT-PCR testing (n = 138)
Recruitment: not stated
Prospective or retrospective: unclear; testing conducted prospectively
Number of samples (samples with confirmed SARS-CoV-2): 138 (94)
Patient characteristics and setting Setting: not stated
Location: samples collected from virology laboratories of 3 university hospital
groups from Assistance-Publique-Hôpitaux de Paris (APHP), (Saint-Antoine-Tenon-
Trousseau, Saint-Louis-Lariboisière and Kremlin Bicêtre-Paul Brousse)
Country: France
Dates: 1-15 April 2020
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: COVID-19 Ag Respi-Strip CORIS (no product code)
Manufacturer: BioConcept, Gembloux, Belgium
Antigen target: SARS-CoV-2 NP
Antibody: monoclonal antibodies
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Test method: CGIA
Samples used: NP swabs in VTM (collection process not described)
Transport media: either of: COPAN UTM 3 mL, Virocult 1 mL, Eswab Amies 1 mL,
4MRT 3 mL, 0.9% NaCl bu&er and cobas ROCHE
Sample storage: no cooling or freezing step used
Test operator: not stated; presume laboratory sta&
Definition of test positivity: not stated; as per manufacturer
Blinding reported: not stated
Timing of samples: not stated; presume on presentation
Target condition and reference standard(s) Reference standard: RT-PCR (different kits used including RealStar Altona®, Anato-
lia®, cobas 6800 Roche®, Allplex™ 2019-nCoV Assay Seegene®)
Definition of non-COVID cases: single negative PCR
Genetic target(s): E gene
Samples used: NP swabs (same as for index)
Timing of reference standard: within a few hours after collection; time post onset of
symptoms not reported
Blinded to index test: unclear
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same sample, both tests conduct-
ed within a few hours
All participants received same reference standard: yes (different kits)
Missing data: none reported
Uninterpretable results: 4 samples collected in cobas VTM gave invalid results and
all samples in cobas medium were excluded
Indeterminate results (index test): control lines reported as "barely visible" for 9
positive and 8 negative tests
Indeterminate results (reference standard): none reported
Unit of analysis: not reported, but samples tested on day of collection so considered
to be 1 per participant
Comparative  
Notes Funding: no funding sources reported
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: no conflict of interest statement reported
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have intro-
duced bias?
  Unclear risk  
Are there concerns that the included pa-
tients and setting do not match the review
question?
    Unclear
DOMAIN 2: Index Test (Antigen tests)
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the
index test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    Unclear
DOMAIN 2: Index Test (Rapid PCR tests)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Unclear    
Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced bias?
  High risk  
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Lambert-Niclot 2020  (Continued)
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)










Cochrane Database of Systematic Reviews
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? No    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling Single-group study to estimate sensitivity and specificity:
- samples submitted for clinical diagnostic testing (n = 169; not all samples analysed for
all tests)
Recruitment: not stated
Prospective or retrospective: retrospective (residual samples)
Number of samples (samples with confirmed SARS-CoV-2): 169 (87)
Patient characteristics and setting Setting: not stated; sampled from laboratory
Location: Washington State Public Health Laboratory
Country: USA
Dates: not stated
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: Xpert Xpress
Manufacturer: Cepheid
Antigen target: E, N2
Antibody: N/A
Test method: rapid PCR
Samples used: NP swabs (collection not described)
Transport media: 300 μL of VTM sample
Sample storage: all same-sample comparisons were performed on specimens
stored at 4 °C for < 72 h with no freeze-thaws
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Test operator: not stated; presume laboratory sta&
Common panel of 26 specimens tested at UW by the UW CDC EUA-based LDT or at Lab-
Corp Seattle
Definition of test positivity: 1 of 2 targets detected was considered positive for all assays;
Xpert Xpress data extracted as per IFU definition (positive = both targets or N gene posi-
tive; E-gene-positive requires retest)
Blinding reported: not stated
Timing of samples: not stated
Also evaluates:
[B] Hologic Panther Fusion RUO, [C] Hologic Panther Fusion EUA, [D] Diasorin Simplexa,
[E] Roche cobas 6800
in same 26 samples and in additional residual specimens (n = 115) at UW (different N per
test)
Target condition and reference stan-
dard(s)
Reference standard: RT-PCR; UW CDC EUA-based in-house test (positive if 1 of 2 targets
detected - presume at < 40 Ct)
Definition of non-COVID cases: single negative PCR
Genetic target(s): NI, N2
Samples used: NP swabs, as for index test
Timing of reference standard: not stated
Blinded to index test: not stated
Incorporated index test: no
Flow and timing Time interval between index and reference tests: all testing conducted within 72 h
All participants received same reference standard: yes
Missing data: none reported; review team excluded data for 28 specimens comparing
Panther Fusion with DiaSorin Simplexa
Uninterpretable results: not stated
Indeterminate results (index test): ‘Inconclusive' results (i.e. 1 genetic target detected)
were considered positive due to the high specificity of all assays and limited cross-reac-
tivity seen for SARS-CoV-2 primer sets. For Xpert Xpress only 12/13 were positive accord-
ing to IFU specifications on first test (both targets present, or N gene positive); on retest-
ing the presumptive positive became positive (detection of E-gene but not N-gene)
Indeterminate results (reference standard): as for index test
Unit of analysis: not stated, only refers to samples
Comparative  
Notes Funding: no funding statement reported
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: no COI statement reported
Methodological quality
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Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Unclear    
Did the study avoid inappropriate inclu-
sions?
Unclear    
Could the selection of patients have in-
troduced bias?
  Unclear risk  
Are there concerns that the included
patients and setting do not match the
review question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Unclear    
If a threshold was used, was it pre-speci-
fied?
Yes    
Could the conduct or interpretation of
the index test have introduced bias?
  Unclear risk  
Are there concerns that the index test,
its conduct, or interpretation differ
from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
No    
Were the reference standard results inter-
preted without knowledge of the results
of the index tests?
Unclear    
Reference standard does not incorporate
result of index test?
Yes    
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
  High risk  
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Are there concerns that the target con-
dition as defined by the reference stan-
dard does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference standard?
Yes    
Did all patients receive the same refer-
ence standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference
standard?
Yes    
Were results presented per patient? Unclear    
Could the patient flow have introduced
bias?





Patient Sampling 2-group study to estimate sensitivity and specificity for diagnosis of active disease
- suspected patients referred for COVID-19 testing at 7 sites according to the local criteria (n = 486); sampled
to enrich for RT-PCR-positive specimens (not further described)
Recruitment: convenience (in addition, 1 site (LAC+USC) tested specimens from a 4-day point prevalence
survey of patients presenting with COVID-19 symptoms)
Prospective or retrospective: retrospective





Johns Hopkins University, Baltimore;
LAC+USC Medical Centre, University of Southern California, Los Angeles;
Manchester University NHS Foundation Trust Manchester;
Mondor Hospital, Paris;
New York City Dept. Health and Mental Hygiene, NYC;
Niguarda Hospital, Milan;
University Hospital, Newark.
Country: USA, UK, France, Italy
Dates: 1 March-2 April 2020
Symptoms and severity: not stated
Demographics: adults at all sites except New York City Dept. Health and Mental Hygiene and Niguarda Hospi-
tal where all age groups were tested (ages not stated)
Exposure history: not stated
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Index tests Test name: Cepheid Xpert Xpress SARS-CoV-2 (RUO version, no product code reported)
Manufacturer: Cepheid Europe
Antigen target: nucleocapsid gene (N2) and the envelope gene (E) (RUO version also detects RdRp gene but
this does not contribute to definition of positive)
Antibody: N/A
Test method: automated point-of-care PCR
Samples used: swabs (NP (n = 339), OP (n = 15), combined NP/OP in the same transport vial (n = 97)), and TA
(n = 30):
1. Baltimore - 61 NP
2. Los Angeles - 88 NP
3. Manchester - 54 NP/OP, 11 NP
4. Paris - 68 NP
5. NYC - NP 11, OP 15, TA 30, NP/OP 43
6. Milan - 79 NP
7. Newark - 21 NP
Transport media: VTM (swabs), diluted in saline (TA). 1 site (Manchester) pretreated specimens with an equal
volume (≥ 30-< 50% (w/w)) of a guanidine hydrochloride bu&er and heated at 80 °C
Sample storage: stored at −80 °C prior to index test, except at 1 site (University Hospital, Newark) where
specimens were tested in real time, within 2 h by the Xpert test (n = 21).
Test operator: not stated; presume laboratory sta&
Definition of test positivity: as per manufacturer: if both targets are detected, or if only N2 is detected, the
test reports a positive result. If only the E target is detected the test reports a presumptive positive result
"because this target is shared among some members of the sarbecovirus subgenus of coronaviruses". The
RUO version of the test shows the amplification curves and PCR cycle threshold for all 3 genetic targets. The
study reports that "The EUA test version cartridge contains the same reagents as the RUO cartridge. The on-
ly difference between the tests is the software which in the EUA version allows the user to see amplification
curves and results for the N2 and E targets only".
Blinding reported: not stated




Reference standard: RT-PCR (sites using each kit not reported, added by review team based on number of
samples per site and per RT-PCR kit)
1. New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)- PCR Diagnostic Panel; NYC
2. Quest SARS-CoV-2 rRT-PCR (Quest Diagnostics, San Juan Capistrano, US); Los Angeles
3. RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany); Baltimore and Paris
4. GeneFinder COVID-19 Plus RealAmp Kit (ELITechGroup, Puteaux, France); Milan
5. Allplex 2019-nCoV Assay (Seegene, Seoul, SK); Milan
6. Charité Virology (Berlin, Germany) (in-house); Manchester
7. Abbott RealTime SARS-CoV-2 Assay (Abbott, Des Plaines, US); Newark
8. Simplexa COVID-19 Direct (DiaSorin, Cypress, US); Newark
Definition of non-COVID cases: yes (performed prior to index test)
Genetic target(s): different targets depending on RT-PCR test used:
1. New York Panel; N (N1, N2)
2. Quest; N (N1, N3)
3. RealStar ; S, E
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4. GeneFinderTM; RdRp, E, N
5. Allplex ; RdRp, E, N
6. Charité Virology; RdRp
7. Abbott RealTime ; RdRp, N
8. Simplexa; ORF1ab, S
Tie-breaker methods (for discrepant results), included: Hologic Panther Fusion (San Diego, USA), Tib-Molbi-
ol LightMix Modular Wuhan Coronavirus E-gene RT-PCR (Roche, Basel, Switzerland); and the CDC assay (IDT
primers and probes)
Samples used: as for index test
Timing of reference standard: as for index test
Blinded to index test: no storage; tested in real time
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same samples but index performed after frozen storage for
undefined period of time except at University Hospital, Newark where specimens were tested in real time,
within 2 h by the Xpert test
All participants received same reference standard: no
Missing data: 4 Xpert Xpress test results were lost permanently due to a single instrument computer malfunc-
tion
Uninterpretable results: 1 Xpert Xpress test was invalid due to a cartridge error (inadequate sample volume)
Indeterminate results (index test) presumptive positive results on Xpert Xpress were not reanalysed by Xpert
Xpress, but all discrepant results were reanalysed by a third RT-PCR method
Indeterminate results (reference standard): specimens with inconclusive results by a test, and those with dis-
crepant results between Xpert and the RT-PCR tests were analysed by a third RT-PCR method
1 FN result was inconclusive on Quest SARS-CoV-2, and negative on CDC RT-PCR; re-considered as TN
Of 11 FPs (including 1 presumptive positive on Xpert Xpress), 2 were negative on both New York SARS-CoV-2
and Panther Fusion (remained as FPs), and 9 were negative on in-house RT-PCR but positive on Roche RT-
PCR (reclassified as TP)
In addition, 12 specimens (8 NP, 4 NP/OP) were inconclusive by the NY (RT)- PCR Diagnostic Panel and con-
sidered positive for data analysis purposes in the study. Of these, 11 were positive by the Xpert test and 1 was
presumptive positive (EUA version of Xpert test). In 4 of these only the N1 target was detected and in 8 only
the N2 target was detected by the New York EUA method, all with Ct values > 36
One NP specimen was inconclusive by the Quest SARS-CoV-2 rRT-PCR test and negative by the Xpert test. The
Quest test reports inconclusive if only a single target (N1 or N3) is detected. They were unable to determine
which target was detected by the Quest test. This specimen was negative by a tie-breaker NAAT.
Unit of analysis: not stated; only samples reported
Comparative  
Notes Funding: not stated; presume funded by test manufacturer (see COI statement)
Publication status: accepted manuscript
Source: Journal of Clinical Microbiolobyogy
Author COI: the study was designed and supervised by the sponsor, Cepheid. Data were collected by inves-
tigators at each study site, and statistical analyses were performed by a Cepheid author. Cepheid authors
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Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
















of patients have in-
troduced bias?




do not match the re-
view question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test
results interpreted
without knowledge
of the results of the
reference standard?
Unclear    
If a threshold was





the index test have
introduced bias?
  Unclear risk  
Are there concerns
that the index test,
its conduct, or in-
terpretation dif-
fer from the review
question?
    High
DOMAIN 3: Reference Standard
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Is the reference stan-
dards likely to cor-
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tation have intro-
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  High risk  
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DOMAIN 4: Flow and Timing
Was there an appro-
priate interval be-
tween index test and
reference standard?
Yes    
Did all patients re-
ceive the same refer-
ence standard?
Yes    
Were all patients in-
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Study characteristics
Patient Sampling Single-group study to estimate sensitivity and specificity for diagnosis of active disease:
- samples from patients suspected of SARS-COV-2 infections (n = 328)
Recruitment: random sampling of samples submitted to 3 laboratories
322/328 NP samples (NP swabs) were randomly selected
Prospective or retrospective: retrospectively
Number of samples (samples with confirmed SARS-CoV-2): 328 (132)
Patient characteristics and set-
ting
Setting: unclear; samples from university laboratories (discussion states that no outpatient pop-
ulation has been sampled, therefore assume inpatients and HCW samples)
Location: laboratories at Université Libre de Bruxelles (LHUB-ULB), UZ Leuven and Centre Hospi-
talier Universitaire Sart-Tilman (CHU) Liège
Country: Belgium
Dates: 19-30 March 2020
Symptoms and severity: not reported
Demographics: not reported
Exposure history: unclear; 53/328 samples were from HCW
Index tests Test name: COVID-19 Ag Respi-Strip
Manufacturer: Coris BioConcept (Belgium)
Antigen target: SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein
Antibody: monoclonal antibodies directed against SARS-CoV and SARS-CoV-2 highly conserved
nucleoprotein antigen
Test method: immunochromatographic assay using colloidal gold (CGIA)
Samples used: remnant respiratory specimens (322 NP swabs, 4 NP aspirate and 2 BAL)
Transport media: NP: flocked swab + UTM 3 mL (or 1 mL of Amies) (Copan, Brescia, Italy);
NPA: 3 mL VTM (veal infusion broth (Difco, Becton Dickinson, Sparks, MD, USA) supplemented
with bovine albumin (Sigma Aldrich, St Louis, MO, USA))
BAL: N/A
Sample storage: not described
Test operator: laboratory technician
Definition of test positivity: visible reddish-purple band appearing at the Test line position (T)
Blinding reported: not stated
Timing of samples: not clear
Target condition and reference
standard(s)
Reference standard: qRT-PCR: RealStar SARS-CoV-2 RT-PCR Kit from Altona-diagnostics with a
cut-o& set at 40 Ct (LHUB-ULB); Roche LC480 thermocycler using Taqman Fast Virus 1-Step Mas-
ter Mix (Thermo Fisher) (Liege); QuantStudio Dx (Thermo Fisher Scientific) or Panther Fusion (PF,
Hologic, San Diego, USA) (UZ Leuven)
Definition of non-COVID cases:
• Genetic target(s): RealStar: not stated;
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• Taqman Fast Virus: RdRp and E genes
• QuantStudio Dx; "slightly adapted" E-gene
• Panther Fusion: E gene and ORF1-ab
Samples used: as for index test (respiratory specimens (322 NP swabs, 4 NP aspirate and 2 BAL)
Timing of reference standard: not stated; same samples as for index test but analysed at time of
collection
Blinded to index test: yes (undertaken for diagnostic purposes at time of collection)
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same samples used; discussion report 'some
delay' between PCR and antigen testing
All participants received same reference standard: yes but different RT-PCR kits
Missing data: no
Uninterpretable results: none reported; discussion reports some difficulties in visualising the
strip through the closed tube requiring the lab technician to open the test tube in the laminar air
flow cabinet and pull out the strip with forceps
Indeterminate results (index test): weak T lines considered positive
Indeterminate results (reference standard): none reported; sensitivity can be extracted for cases
with Ct values < or > 25 (high vs lower viral load)
Unit of analysis: refers to participants
Comparative  
Notes Funding: not stated
Publication status: preprint (not peer-reviewed)
Sourcepreprint server (medRxiv)
Author COI: the IVD medical device has been developed by the investigator Pascal Mertens, Hen-
ri Magein, and Justine Bouzet working for Coris BioConcept (potential conflict of interest de-
clared even though they don’t have any share in this company); Thierry Leclipteux was involved
in the development of this test and is the CEO of Coris
Bioconcept (potential conflict of interest declared). All scientific investigators that are external
to Coris BioConcept declare having no conflict of interest.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes    
Was a case-control design avoid-
ed?
Yes    
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Did the study avoid inappropriate
inclusions?
Yes    
Could the selection of patients
have introduced bias?
  Low risk  
Are there concerns that the in-
cluded patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (Antigen tests)
Were the index test results inter-
preted without knowledge of the
results of the reference standard?
Unclear    
If a threshold was used, was it
pre-specified?
Yes    
Could the conduct or interpre-
tation of the index test have in-
troduced bias?
  Unclear risk  
Are there concerns that the in-
dex test, its conduct, or inter-
pretation differ from the re-
view question?
    High
DOMAIN 2: Index Test (Rapid PCR tests)
DOMAIN 3: Reference Standard
Is the reference standards like-
ly to correctly classify the target
condition?
No    
Were the reference standard re-
sults interpreted without knowl-
edge of the results of the index
tests?
Unclear    
Reference standard does not in-
corporate result of index test?
Yes    
Could the reference standard,
its conduct, or its interpreta-
tion have introduced bias?
  High risk  
Are there concerns that the tar-
get condition as defined by the
reference standard does not
match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval
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Did all patients receive the same
reference standard?
Yes    
Were all patients included in the
analysis?
Yes    
Did all participants receive a ref-
erence standard?
Yes    
Were results presented per pa-
tient?
Yes    
Could the patient flow have in-
troduced bias?





Patient Sampling Single-group study to estimate sensitivity and specificity for diagnosis of active
disease:
- samples positive and negative on 1 of 2 SARS-CoV-2 RT-PCR assays
Recruitment: not stated; suggests possible deliberate sampling of positive cases
Prospective or retrospective: retrospective (residual samples)
Number of samples (samples with confirmed SARS-CoV-2): 61 (46)
Patient characteristics and setting Setting: not stated; 2 independent laboratories (Class II biosafety cabinet (BSC))
Location: not stated; author institutions University of Pittsburgh School of Med-
icine, Pittsburgh and Laboratory of Viral Diseases, Wadsworth Centre, New York
State Department of Health, Albany, NY
Country: USA
Dates: not stated
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: ID NOW COVID-19 (product code not reported)
Manufacturer: Abbott, Chicago, USA
Antigen target: not stated
Antibody: N/A
Test method: not stated (should be isothermal PCR)
Samples used: NP samples (residual samples)
Transport media: VTM; no further detail (no longer covered on IFU)
Sample storage: stored at −80 ℃ prior to testing
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Test operator: certified laboratory personnel
Definition of test positivity: not stated; as per manufacturer
Blinding reported: not stated
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: CDC EUA or the New York EUA RT-PCR assays
Definition of non-COVID cases: single RT-PCR negative
Genetic target(s): not stated
Samples used: as for index test
Timing of reference standard: as for index test
Blinded to index test: not stated; samples analysed at or near time of collection
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same samples but used at dif-
ferent times (samples used for index test stored at −80 ℃)
All participants received same reference standard: no, either the CDC EUA or the
New York EUA assays
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): none reported
Indeterminate results (reference standard): none reported
Unit of analysis: not stated; only samples reported
Comparative  
Notes Funding: not stated
Publication status: accepted manuscript
Source: Journal of Clinical Virology
Author COI: COI not mentioned by study authors
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
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Could the selection of patients have introduced
bias?
  Unclear risk  
Are there concerns that the included patients
and setting do not match the review question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the in-
dex test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its con-
duct, or interpretation differ from the review
question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Yes    
Reference standard does not incorporate result of
index test?
Yes    
Could the reference standard, its conduct, or
its interpretation have introduced bias?
  High risk  
Are there concerns that the target condition
as defined by the reference standard does not
match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference standard? Yes    
Were results presented per patient? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
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Patient Sampling 2-group study to estimate sensitivity and specificity:
- samples from symptomatic (fever or cough or shortness of breath) adult and paediatric
outpatients, ED patients, and inpatients
Recruitment: consecutive (first 94 participants), then all PCR-positive samples plus the next
PCR-negative sample after each positive sample, to a total of 200 samples
Prospective or retrospective: retrospective (participant and sample details extracted from
the electronic medical record)
Number of samples (samples with confirmed SARS-CoV-2): 200 (125)
Patient characteristics and setting Setting: mixed (outpatients, ED patients and inpatients)
Location: Rush University Medical Centre (RUMC) or Rush Oak Park Hospital (ROPH), Chica-
go
Country: USA
Dates: 27 March-9 April 2020
Symptoms and severity: 79 (39.5%) hospitalised including 29 in ICU, 76 (38%) ambulatory
care including 55 seen in a designated COVID-19 screening clinic), and 45 (23%) seen at ED
Demographics: mean age 50 years (SD 17 years), 92 (46%) men
Exposure history: not stated




Test method: rapid PCR (isothermal)
Samples used: NP swabs in 3 mL VTM (collection not reported)
Transport media: M4-RT VTM (Remel, Lenexa, KS)
Sample storage: stored at 4 °C if all testing could not be completed on the same day; all
tests completed within 72 h of collection
Test operator: not stated; presume laboratory sta&
Definition of test positivity: as per manufacturer
Blinding reported: not stated
Timing of samples: not stated; presumably on presentation but no information on symp-
tom status
Target condition and reference stan-
dard(s)
Reference standard: RT-PCR; 2 methods used in the study
1. modified CDC RT-PCR (positive result required Ct < 40 for both targets; negative if neither
target detected and positive amplification curve for control (RP) gene; inconclusive if only
1 target detected at Ct < 40, and test repeated)
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2. Abbott RealTime SARS-CoV-2 RT-PCR (amplification curves reported as detected or not
detected)
Record review used to verify status of 8 samples positive on RealTime assay and negative
(6) or inconclusive (2) on CDC assay (all considered disease-positive)




Samples used: NP swabs in VTM, as for index test
Timing of reference standard: not stated
Blinded to index test: not stated
Incorporated index test: no
Flow and timing Time interval between index and reference tests: all 3 tests conducted within 72 h of sam-
ple collection
All participants received same reference standard: no? (all received both RT-PCR tests, only
discordant results on RT-PCR had record review)
Missing data: none reported
Uninterpretable results: 2 results were invalid on ID NOW and were not retested (excluded)
Indeterminate results (index test): none reported
Indeterminate results (reference standard): discordant results between 2 RT-PCR assays
had record review to determine presence/absence COVID-19 infection
Unit of analysis: participants (specimens from 200 unique participants)
Comparative  
Notes Funding: none reported (some reagents supplied from NIH)
Publication status: preprint
Source: medRxiv
Author COI: no COI statement was reported
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample
of patients enrolled?
No    
Was a case-control design avoided? No    
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Did the study avoid inappropriate in-
clusions?
Yes    
Could the selection of patients have
introduced bias?
  High risk  
Are there concerns that the includ-
ed patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpret-
ed without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-
specified?
Yes    
Could the conduct or interpretation
of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
Yes    
Were the reference standard results in-
terpreted without knowledge of the re-
sults of the index tests?
Unclear    
Reference standard does not incorpo-
rate result of index test?
Yes    
Could the reference standard, its
conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target
condition as defined by the refer-
ence standard does not match the
question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
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Did all patients receive the same refer-
ence standard?
Yes    
Were all patients included in the analy-
sis?
No    
Did all participants receive a reference
standard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have intro-
duced bias?





Patient Sampling Single-group study to estimate sensitivity and specificity:
- specimens collected from inpatients and ambulatory patients at the University
of Chicago
Recruitment: not stated
Prospective or retrospective: not stated
Number of samples (samples with confirmed SARS-CoV-2): 103 (42)
Patient characteristics and setting Setting: inpatient and ambulatory; samples selected from central laboratory
Location: Clinical Microbiology Laboratory, University of Chicago
Country: USA
Dates: not stated
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: Xpert Xpress SARS-CoV-2 assay (no product code)
Manufacturer: Cepheid, Sunnyvale, CA
Antigen target: E, N (N2 region)
Antibody: N/A
Test method: rapid PCR
Samples used: 8 nasal and 95 NP swabs
Transport media: none described
Sample storage: not stated
Test operator: not stated; presume laboratory sta&
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Definition of test positivity: not stated; re-testing using Xpert Xpress was under-
taken for an N-gene positive result due discrepancy with RT-PCR (not in line with
IFU recommendation)
Blinding reported: not stated
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: Roche cobas SARS-CoV-2 assay on the cobas 6800 system
(Roche Molecular Systems, Branchburg, NJ)
Definition of non-COVID cases: single RT-PCR negative
Genetic target(s): ORF1, E
Samples used: nasal and NP swabs; same as for index test
Timing of reference standard: not stated
Blinded to index test: not stated
Incorporated index test: no
Flow and timing Time interval between index and reference tests: not stated; same sample and
appear to have both been conducted soon after sample collection
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): single FP (negative on E gene and low posi-
tive on N gene) was retested with Xpert Xpress and considered negative on both
targets
Indeterminate results (reference standard): single FP was retested on RT-PCR
and found to be repeatedly negative
Unit of analysis: refers to participants
Comparative  
Notes Funding: none described
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: no COI statement was reported
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients
enrolled?
Unclear    
Was a case-control design avoided? Yes    
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Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have introduced
bias?
  Unclear risk  
Are there concerns that the included patients
and setting do not match the review question?
    Unclear
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Unclear    
If a threshold was used, was it pre-specified? No    
Could the conduct or interpretation of the in-
dex test have introduced bias?
  High risk  
Are there concerns that the index test, its con-
duct, or interpretation differ from the review
question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly clas-
sify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the index
tests?
Unclear    
Reference standard does not incorporate result of
index test?
Yes    
Could the reference standard, its conduct, or
its interpretation have introduced bias?
  Unclear risk  
Are there concerns that the target condition
as defined by the reference standard does not
match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index
test and reference standard?
Yes    
Did all patients receive the same reference stan-
dard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference standard? Yes    
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Were results presented per patient? Yes    





Patient Sampling 2-group study to estimate sensitivity and specificity for diagnosis of active disease:
- samples from suspected COVID-19 cases (n = 1453) with deliberate sampling of
PCR-positive and negative cases on a 2:1 basis (n = 127)
Recruitment: convenience sampling
Prospective or retrospective: retrospectively
Number of samples (samples with confirmed SARS-CoV-2): 127 (82)
Patient characteristics and setting Setting: outpatients attending ED at private medical centre (hospital)
Location: Clínica Alemana, Santiago
Country: Chile
Dates: 16-21 March 2020
Symptoms and severity: cough 94 (74.6%)
Fever 77 (61.1%)
Median duration of symptoms of 2 days (IQR 1–4; range 0-12)
Duration of symptoms: day 0-3 91 (72.2%); day 4-7 27 (22.4%); day ≥ 8 8 (6.3%)
Demographics: 68 male (53.5%), median age 38 years (IQR 29.5–44; range 1–91)
Exposure history: not stated
Index tests Test name: diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Cat. N°
YRLF04401025, lot N° 2002N408)
Manufacturer: Bioeasy Biotechnology Co., Shenzhen, China
Antigen target: SARS-CoV-2 nucleocapsid protein
Antibody: not stated
Test method: FIA
Samples used: remnant (?) OP and NP swabs in 3 mL UTM
Transport media: UTM-RT System, Copan Diagnostics, Murrieta, CA, USA
Sample storage: stored at 4 °C and tested within 48 h
Test operator: laboratory technician
Definition of test positivity: not stated; test "automatically delivers a positive or neg-
ative qualitative result"
Positive or negative defined qualitatively
Blinding reported: yes
Timing of samples: on presentation
Porte 2020 
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)










Cochrane Database of Systematic Reviews
Within 48 h of the PCR test but it doesn't say when PCR test was performed (median
duration of symptoms reported in D9)
Target condition and reference standard(s) Reference standard: RT-PCR (COVID-19 Genesig Real-Time PCR assay (Primer Design
Ltd., Chandler's Ford, UK)); Ct ≤ 40 considered positive
Definition of non-COVID cases: single RT-PCR negative
Genetic target(s): not stated
Samples used: as for index test; same OP and NP swabs used
Timing of reference standard: median 2 d post symptom onset (IQR 1-4; range 0-12)
Blinded to index test: yes (index test done within 48 h of PCR test)
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same sample used; within 48 h
All participants received same reference standard: yes
Missing data: no
Uninterpretable results: not reported
Indeterminate results (index test): not reported
Indeterminate results (reference standard): not reported
Unit of analysis: participants
Comparative  
Notes Funding: this work did not receive funding
Publication status: preprint (not peer-reviewed)
Source: SSRN
Author COI: all study authors declare no competing interests
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Yes    
Could the selection of patients have intro-
duced bias?
  High risk  
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Are there concerns that the included pa-
tients and setting do not match the review
question?
    High
DOMAIN 2: Index Test (Antigen tests)
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the
index test have introduced bias?
  Low risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    High
DOMAIN 2: Index Test (Rapid PCR tests)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Yes    
Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced bias?
  High risk  
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?
  Low risk  
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Patient Sampling Single-group study to estimate sensitivity:
- samples positive using standard of care testing (n = 96)
(14 negative controls (UTM) included to control for carry-over contamination only)
Recruitment: convenience
Prospective or retrospective: retrospective (remnant samples)
Number of samples (samples with confirmed SARS-CoV-2): 96 (96)
Patient characteristics and setting Setting: not stated; includes self-collected and provided-collected samples
Location: not stated; author institutions University Hospitals Cleveland Medical
Centre
and Case Western Reserve University
Country: USA
Dates: not stated
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: ID NOW (product codes not reported)
Manufacturer: Abbott; Chicago, USA
Also reports evaluation of Diasorin Simplexa (not eligible for this review)
Antigen target: not stated
Antibody: N/A
Test method: isothermal PCR
Samples used: nasal swabs (self-collected) and NP swabs (provider collected); all
remnant samples
Transport media: nasal swabs (2 mL normal saline) and NP swabs (3 mL UTM)
Sample storage: not stated
Test operator: not stated; presume laboratory sta&
Definition of test positivity: not stated; as per manufacturer
Blinding reported: not stated
Timing of samples: not stated
Target condition and reference standard(s) Reference standard: standard of care testing for original samples; remnant samples
re-tested with modified CDC RT-PCR (using 7500 Fast instrument and using alternate
RNA extraction method (Maxwell RSC 6 instrument with Viral TNA Kit (Cat# AS1330;
Promega, Madison, USA)); samples with 1 positive target detected considered posi-
tive instead of "inconclusive"
Definition of non-COVID cases: as for index test
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Genetic target(s): N1 and N2
Samples used: as for index test
Timing of reference standard: as for index test
Blinded to index test: as for index test
Incorporated index test: as for index test
Flow and timing Time interval between index and reference tests: same samples used
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): none reported
Indeterminate results (reference standard): RT-PCR detected only 1 of 2 targets for
2 samples (both considered positive (diagnosed as positive on original sample test-
ing); both were negative on index test)
Unit of analysis: not stated; only samples reported
Comparative  
Notes Funding: no outside funding used to support the investigation
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: COI not mentioned by study authors
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have intro-
duced bias?
  High risk  
Are there concerns that the included pa-
tients and setting do not match the review
question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
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Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Unclear    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the
index test have introduced bias?
  Unclear risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
Yes    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Unclear    
Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced bias?
  Unclear risk  
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Unclear    
Could the patient flow have introduced
bias?





Patient Sampling 2-group study to estimate sensitivity and specificity:
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- patients undergoing routine clinical testing by RT-PCR (n = 113)
Recruitment: unclear; describes deliberate sampling of samples with high, medium
and low Ct values on the reference standard RT-PCR
Prospective or retrospective: unclear; residual swabs used but testing undertaken
within 48 h of sample collection
Number of samples (samples with confirmed SARS-CoV-2): 113 (88)
Patient characteristics and setting Setting: inpatient and ED (n from each not reported)
Location: not stated; author institution is Columbia University Irving Medical Centre
Country: USA
Dates: 8-13 April 2020
Symptoms and severity: not stated
Demographics: 111 adult (range 23-101 years; average 65 years for RT-PCR-positive
and 43 years for RT-PCR-negative); 2 paediatric (age 1 day and 5 days)
61, 54% male
Exposure history: not stated
Index tests Test name: [A] ID NOW (see Smithgall 2020 [B] for details of comparator test)
(product codes not reported)
Manufacturer: [A] Abbott
Antigen target: [A] RdRp gene
Antibody: N/A
Test method: [A] isothermal PCR
Samples used: residual NP swabs (collection not described)
Transport media: 3 mL VTM (M4RT VTM; ThermoFisher Scientific, Waltham, MA) or
UTM (UTM; Becton Dickinson and Co., Franklin Lakes, NJ)
Sample storage: stored at 4 °C; testing completed within 48 h of sample collection
Test operator: not stated; presume laboratory sta&
Definition of test positivity: automated as per manufacturer
Blinding reported: not stated
Timing of samples: not stated; presume on admission or presentation at ED
Target condition and reference standard(s) Reference standard: RT-PCR with cobas SARS-CoV-2 assay on the 6800 platform
(Roche Diagnostics, Indianapolis, IN); threshold not stated, all Ct values < 37 on both
target genes
Definition of non-COVID cases: not stated; presume single RT-PCR negative
Genetic target(s): ORF1 a/b, E-gene
Samples used: as for index test
Timing of reference standard: as for index test
Blinded to index test: as for index test
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Incorporated index test: no
Flow and timing Time interval between index and reference tests: simultaneous; same samples used
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results:
Indeterminate results (index test): Xpert: 1 sample was a presumptive positive
based on detection of E-gene target but not the N2 target
Indeterminate results (reference standard): none reported
Unit of analysis: participants
Comparative  
Notes Funding: none reported
Publication status: published
Source: Journal of Clinical Virology
Author COI: study authors report no conflicts of interest present
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of pa-
tients enrolled?
No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Unclear    
Did the study avoid inappropriate inclusions? Unclear    
Could the selection of patients have intro-
duced bias?
  High risk  
Are there concerns that the included pa-
tients and setting do not match the review
question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted with-
out knowledge of the results of the reference
standard?
Unclear    
If a threshold was used, was it pre-specified? No    
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Could the conduct or interpretation of the
index test have introduced bias?
  High risk  
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly
classify the target condition?
No    
Were the reference standard results interpret-
ed without knowledge of the results of the in-
dex tests?
Unclear    
Reference standard does not incorporate re-
sult of index test?
Yes    
Could the reference standard, its conduct,
or its interpretation have introduced bias?
  High risk  
Are there concerns that the target condi-
tion as defined by the reference standard
does not match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval between in-
dex test and reference standard?
Yes    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Unclear    
Did all participants receive a reference stan-
dard?
Yes    
Were results presented per patient? Yes    
Could the patient flow have introduced
bias?





Patient Sampling See Smithgall 2020 [A] for full study details and QUADAS-2 entries
Patient characteris-
tics and setting
See Smithgall 2020 [A] for full study details and QUADAS-2 entries
Index tests Test name: [B] Xpert Xpress (product codes not reported) (see Smithgall 2020 [A] for details of comparator
test)
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Manufacturer: [B] Cepheid
Antigen target: [B] N2, E genes
Antibody: N/A
Test method: [B] automated RT-PCR
Samples used: residual NP swabs (collection not described)
Transport media: 3 mL VTM (M4RT VTM; ThermoFisher Scientific, Waltham, MA) or UTM (UTM; Becton Dickin-
son and Co., Franklin Lakes, NJ)
Sample storage: stored at 4 °C; testing completed within 48 h of sample collection.
Test operator: not stated; presume laboratory sta&
Definition of test positivity: automated as per manufacturer
Blinding reported: not stated




See Smithgall 2020 [A] for full study details and QUADAS-2 entries
Flow and timing See Smithgall 2020 [A] for full study details and QUADAS-2 entries
Comparative  





Patient Sampling Single-group study to estimate sensitivity and specificity:
- samples from patients with respiratory symptoms and/or fever attending a private hospital
ED
Recruitment: convenience with deliberate sampling of positive cases to ensure a 2:1 distribu-
tion reported (5276 samples processed during study period)
Prospective or retrospective: retrospective
Number of samples (samples with confirmed SARS-CoV-2): 111 (80)
*17 samples included in Porte 2020
Patient characteristics and setting Setting: ED (private hospital)
Location: Clínica Alemana de Santiago
Country: Chile
Dates: 16 March-26 April 2020
Symptoms and severity: respiratory symptoms and/or fever; no further detail
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Demographics: median age 40 years; 50, 45% male (median age 38 years, 43% male for all sam-
ples tested during period)
Exposure history: none reported
Index tests Weitzel 2020 [A] entry is for test [A] in the list below
Test name:
[A] Biocredit COVID-19 Ag One Step SARS-CoV-2 Antigen Test (RapiGEN Inc., Anyang-si,
Gyeonggi-do, Republic of Korea)
[B] COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test (Liming Bio-Prod-
ucts Co., Jiangsu, China)
[C] Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence im-
munochromatography) (Savant Biotechnology Co., Beijing, China),
[D] Diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Fluorescence Immunochro-
matographic Assay) (Bioeasy Biotechnology Co., Shenzhen, China).
Manufacturer:
[A] RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea
[B] Liming Bio-Products Co., Jiangsu, China
[C] Savant Biotechnology Co., Beijing, China
[D] Bioeasy Biotechnology Co., Shenzhen, China
Antigen target: not reported in study
Antibody: not reported in study
Test method: [A] and [B] CGIA
[C] and [D] FIA
Samples used: NOP swabs in 3 mL UTM
Transport media: UTM-RT System (Copan Diagnostics, Murrieta, CA, USA)
Sample storage: stored at −80 °C; index tests applied on 28 and 29 April 2020
Test operator: single, trained laboratory technician under BSL2 cabinet; visual outputs read by
2 independent observers with referral to third if needed
Definition of test positivity: as per manufacturer; Beijing Savant test required use of manufac-
turer supplied UV torch due to unavailability of reader device in Chile
Blinding reported: yes; blinding stated
Timing of samples: median 2 days (IQR 1-5 days); 88% (96/109) during the first week of symp-
toms
Target condition and reference
standard(s)
Reference standard: RT-PCR; COVID-19 Genesig Real-Time PCR assay (Primerdesign Ltd., Chan-
dler's Ford, UK). Ct ≤ 40 considered positive
Definition of non-COVID cases: single PCR negative
Genetic target(s): RdRp
Samples used: NOP swabs; as for index
Timing of reference standard: as for index test; median 2 days (IQR 1-5 days)
Blinded to index test: yes; prior to index
Incorporated index test: no
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Flow and timing Time interval between index and reference tests: same samples; index tests conducted after
frozen storage
All participants received same reference standard: yes
Missing data: none reported; evaluation of Liming test was discontinued after initial poor per-
formance (zero TP)
Uninterpretable results: 2 tests had invalid results due to insufficient liquid migration (2 results
excluded for each test)
Indeterminate results (index test): visual interpretation of the Beijing Savant assay (using man-
ufacturer supplied UV torch) was reportedly difficult under daylight conditions; manufacturer's
fluorescence reader not available in Chile.
Indeterminate results (reference standard): none reported
Unit of analysis: participants
Comparative  
Notes Funding: study authors report that the work received no funding; Savant Biotechnology Co.
provided test kits free of charge
Publication status: preprint
Source: medRxiv
Author COI: all authors declare no competing interests
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sam-
ple of patients enrolled?
No    
Was a case-control design avoid-
ed?
No    
Did the study avoid inappropriate
exclusions?
Unclear    
Did the study avoid inappropriate
inclusions?
Yes    
Could the selection of patients
have introduced bias?
  High risk  
Are there concerns that the in-
cluded patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (Antigen tests)
Were the index test results inter-
preted without knowledge of the
results of the reference standard?
Yes    
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If a threshold was used, was it pre-
specified?
Yes    
Could the conduct or interpreta-
tion of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the in-
dex test, its conduct, or inter-
pretation differ from the review
question?
    High
DOMAIN 2: Index Test (Rapid PCR tests)
DOMAIN 3: Reference Standard
Is the reference standards likely to
correctly classify the target condi-
tion?
No    
Were the reference standard re-
sults interpreted without knowl-
edge of the results of the index
tests?
Yes    
Reference standard does not in-
corporate result of index test?
Yes    
Could the reference standard,
its conduct, or its interpretation
have introduced bias?
  High risk  
Are there concerns that the tar-
get condition as defined by the
reference standard does not
match the question?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval
between index test and reference
standard?
Yes    
Did all patients receive the same
reference standard?
Yes    
Were all patients included in the
analysis?
No    
Did all participants receive a refer-
ence standard?
Yes    
Were results presented per pa-
tient?
Yes    
Could the patient flow have in-
troduced bias?
  High risk  
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Index tests Weitzel 2020 [B] entry is for test [B] in the list below; see Weitzel 2020 [A] for full study details and QUADAS en-
tries
Test name:
[A] Biocredit COVID-19 Ag One Step SARS-CoV-2 Antigen Test (RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic
of Korea)
[B] COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test (Liming Bio-Products Co.,
Jiangsu, China)
[C] Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence immunochromatography)
(Savant Biotechnology Co., Beijing, China),
[D] Diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Fluorescence Immunochromatographic As-
say) (Bioeasy Biotechnology Co., Shenzhen, China).
Manufacturer:
[A] RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea
[B] Liming Bio-Products Co., Jiangsu, China
[C] Savant Biotechnology Co., Beijing, China
[D] Bioeasy Biotechnology Co., Shenzhen, China
Antigen target: not reported in study
Antibody: not reported in study
Test method: [A] and [B] CGIA
[C] and [D] FIA
Samples used: NOP swabs in 3 mL UTM
Transport media: UTM-RT System (Copan Diagnostics, Murrieta, CA, USA)
Sample storage: stored at −80 °C; index tests applied on 28 and 29 April 2020
Test operator: single, trained laboratory technician under BSL2 cabinet; visual outputs read by 2 independent
observers with referral to third if needed
Definition of test positivity: as per manufacturer; Savant test required use of manufacturer supplied UV torch
due to unavailability of reader device in Chile
Blinding reported: yes; blinding stated




See Weitzel 2020 [A] for full study details and QUADAS entries
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Patient Sampling See Weitzel 2020 [A] for full study details and QUADAS entries
Patient characteris-
tics and setting
See Weitzel 2020 [A] for full study details and QUADAS entries
Index tests Weitzel 2020 [C] entry is for test [C] in the list below; see Weitzel 2020 [A] for full study details and QUADAS en-
tries
Test name:
[A] Biocredit COVID-19 Ag One Step SARS-CoV-2 Antigen Test (RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic
of Korea)
[B] COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test (Liming Bio-Products Co., Jiangsu,
China)
[C] Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence immunochromatog-
raphy) (Savant Biotechnology Co., Beijing, China),
[D] Diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Fluorescence Immunochromatographic As-
say) (Bioeasy Biotechnology Co., Shenzhen, China).
Manufacturer:
[A] RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea
[B] Liming Bio-Products Co., Jiangsu, China
[C] Savant Biotechnology Co., Beijing, China
[D] Bioeasy Biotechnology Co., Shenzhen, China
Antigen target: not reported in study
Antibody: not reported in study
Test method: [A] and [B] CGIA
[C] and [D] FIA
Samples used: NOP swabs in 3 mL UTM
Transport media: UTM-RT System (Copan Diagnostics, Murrieta, CA, USA)
Sample storage: stored at −80 °C; index tests applied on 28 and 29 April 2020
Test operator: single, trained laboratory technician under BSL2 cabinet; visual outputs read by 2 independent
observers with referral to third if needed
Definition of test positivity: as per manufacturer; Savant test required use of manufacturer supplied UV torch
due to unavailability of reader device in Chile
Blinding reported: yes; blinding stated




See Weitzel 2020 [A] for full study details and QUADAS entries
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Patient Sampling See Weitzel 2020 [A] for full study details and QUADAS entries
Patient characteris-
tics and setting
See Weitzel 2020 [A] for full study details and QUADAS entries
Index tests Weitzel 2020 [D] entry is for test [D] in the list below; see Weitzel 2020 [A] for full study details and QUADAS en-
tries
Test name:
[A] Biocredit COVID-19 Ag One Step SARS-CoV-2 Antigen Test (RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic
of Korea)
[B] COVID-19 Antigen Rapid Test Device StrongStep® COVID-19 Antigen Test (Liming Bio-Products Co., Jiangsu,
China)
[C] Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence immunochromatography)
(Savant Biotechnology Co., Beijing, China),
[D] Diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Fluorescence Immunochromato-
graphic Assay) (Bioeasy Biotechnology Co., Shenzhen, China).
Manufacturer:
[A] RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea
[B] Liming Bio-Products Co., Jiangsu, China
[C] Savant Biotechnology Co., Beijing, China
[D] Bioeasy Biotechnology Co., Shenzhen, China
Antigen target: not reported in study
Antibody: not reported in study
Test method: [A] and [B] CGIA
[C] and [D] FIA
Samples used: NOP swabs in 3 mL UTM
Transport media: UTM-RT System (Copan Diagnostics, Murrieta, CA, USA)
Sample storage: stored at −80°C; index tests applied on 28 and 29 April 2020
Test operator: single, trained laboratory technician under BSL2 cabinet; visual outputs read by 2 independent
observers with referral to third if needed
Definition of test positivity: as per manufacturer; Savant test required use of manufacturer supplied UV torch
due to unavailability of reader device in Chile
Blinding reported: yes; blinding stated




See Weitzel 2020 [A] for full study details and QUADAS entries
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Patient Sampling 2-group study to estimate sensitivity and specificity for diagnosis of active disease:
- samples selected from laboratories on the basis of presence/absence of 2 genetic targets on RT-
PCR: SARS-CoV-2 E-gene +/RdRp gene + (n = 30); SARS-CoV-2 E-gene +/RdRp gene – (n = 28); SARS-
CoV-2 E-gene -/RdRp gene (n = 30)
(A separate set of samples were tested in triplicate at all 3 laboratories to determine limits of de-
tection and analytical specificity)
Recruitment: not stated; deliberate sampling used
Prospective or retrospective: retrospective
Sample size (cases): 88 (58)
Patient characteristics and set-
ting
Setting: not stated; 3 laboratories
Location: Radboud UMC in Nijmegen, PAMM in Veldhoven and the RIVM in Bilthoven
Country: The Netherlands
Dates: January-March 2020
Symptoms and severity: not stated
Demographics: not stated
Exposure history: not stated
Index tests Test name: Cepheid Xpert Xpress SARS-CoV-2 (product code not reported)
Manufacturer: Cepheid Europe
Antigen target: E-gene (sarbeco-specific) and N2-gene (SARS-CoV-2-specific)
Antibody: N/A
Test method: not stated (it should be automated PCR)
Samples used: NP or mid-turbinate, and OP swabs
Transport media: UTM or GLY medium; no further details
Sample storage: stored at −80 ℃
Test operator: not stated; presume laboratory sta&
Definition of test positivity: as per manufacturer; reported E-gene-only positive specimens as pre-
sumptive positive but no re-testing with Xpert Xpress was reported. N2-only positives were con-
sidered positive (but re-tested with RT-PCR)
Blinding reported: not stated (see comment section)
Timing of samples: not stated
Target condition and reference
standard(s)
Reference standard: in-house RT-PCR:
Radboud UMC Lab: MagNApure 96 (Roche) (isolation platform); MagNApure 96 DNA and Viral NA
Small Volume (extraction kit); Roche LC480 II (PCR platform); Life Technologies Taqman FastVirus
1-step mastermix (RT-PCR mastermix)
PAMM Lab: Roche cobas 4800 (isolation platform); CT/NG extraction protocol (extraction kit);
Roche LC480 II (PCR platform); Roche LightCycler Multiplex RNA Virus Master (RT-PCR mastermix);
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RIVM Lab: BioMérieux NucliSens (isolation platform); easyMAG EasyMAG extraction reagents (ex-
traction kit); Thermo Fisher QuantStudio 6 (PCR platform); Life Technologies Taqman FastVirus 1-
step mastermix (RT-PCR mastermix)
Definition of non-COVID cases: yes (performed prior to index test)
Genetic target(s): Radboud UMC lab: E-gene and RdRp-gene
PAMM Lab: started with E-gene and RdRp-gene and mid-March moved on to E-gene testing only
RIVM Lab: started with E-gene and RdRp-gene and at the beginning of April moved on to E-gene
and CDC N1-gene primer and probes
Samples used: as for index test
Timing of reference standard: as for index test
Blinded to index test: storage prior to freezing was not reported; samples were analysed at or near
time of collection ("processed … in the routine diagnostic procedure using the locally implement-
ed RT-PCR")
Incorporated index test: no
Flow and timing Time interval between index and reference tests: same samples used; index text seems to have
been conducted after frozen storage
All participants received same reference standard: no, 3 different in-house PCR based on the labo-
ratory
Missing data: none reported
Uninterpretable results: none reported
Indeterminate results (index test): 1 sample was positive only on N2 gene (positive according to
IFU) and 1 was positive only on E gene (presumptive positive, requires re-testing according to
IFU). Both samples were re-tested on RT-PCR only
Indeterminate results (reference standard): re-testing of the two ‘FN’ samples (one TP and 1 pre-
sumptive positive according to IFU definition) with RT-PCR found both samples to be disease-neg-
ative (reclassed as 1 TN and 1 FP); study authors note that the viral loads of these samples are at
the limit of detection for Xpert Xpress and that multiple freeze-thaw steps of samples could have
had a significant impact on detection.
Unit of analysis: not stated; only samples reported
Comparative  
Notes Funding: not stated
Publication status: accepted manuscript
Source: Journal of Clinical Virology
Author COI: the study authors declare no COI present
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No    
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Was a case-control design
avoided?
No    
Did the study avoid inappropri-
ate exclusions?
Unclear    
Did the study avoid inappropri-
ate inclusions?
Unclear    
Could the selection of patients
have introduced bias?
  High risk  
Are there concerns that the in-
cluded patients and setting
do not match the review ques-
tion?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results in-
terpreted without knowledge
of the results of the reference
standard?
Unclear    
If a threshold was used, was it
pre-specified?
No    
Could the conduct or interpre-
tation of the index test have
introduced bias?
  High risk  
Are there concerns that the in-
dex test, its conduct, or inter-
pretation differ from the re-
view question?
    High
DOMAIN 3: Reference Standard
Is the reference standards like-
ly to correctly classify the target
condition?
No    
Were the reference standard re-
sults interpreted without knowl-
edge of the results of the index
tests?
Yes    
Reference standard does not in-
corporate result of index test?
Yes    
Could the reference standard,
its conduct, or its interpreta-
tion have introduced bias?
  High risk  
Are there concerns that the
target condition as defined by
    High
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the reference standard does
not match the question?
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes    
Did all patients receive the
same reference standard?
Yes    
Were all patients included in the
analysis?
Unclear    
Did all participants receive a ref-
erence standard?
Yes    
Were results presented per pa-
tient?
Unclear    
Could the patient flow have
introduced bias?





Patient Sampling 2-group study to estimate sensitivity and specificity:
- samples from symptomatic patients of all ages and gender
Recruitment: not stated; specimens selected to represent the true positivity rate at au-
thors' institution (50% to 60%), and to span low and high viral loads
Prospective or retrospective: mixed; included frozen samples (n = 88) and prospectively
tested (n = 20)
Number of samples (samples with confirmed SARS-CoV-2):108 (58)
Patient characteristics and setting Setting: not stated; selected from laboratory
Location: not stated; authors' institutions were Northwell Health Laboratories, and Dept
Pathology and Laboratory Medicine, The Donald and Barbara Zucker School of Medicine
Country: USA
Dates: March-April 2020
Symptoms and severity: "symptomatic"; no further details
Demographics: not stated (all ages and genders)
Exposure history: not stated
Index tests Zhen 2020 [A] is the entry for test [A] from the list below
Test name:
[A] Xpert® Xpress SARS-CoV-2
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[B] ID NOW COVID-19
(no product codes reported)
Manufacturer: [A] Cepheid, [B] Abbott
Antigen target: [A] N2, E; [B] RdRp
Antibody: N/A
Test method: rapid PCR
Samples used: NP swabs
Transport media: UTM (various manufacturers)
Sample storage: on collection, stored at 2-8 0C for up to 72 h; after routine testing, stored
at −80 0C
88 samples tested using ePlex on collection, then frozen prior to testing with ID NOW,
Xpert Xpress and Hologic RT-PCR; 20 samples tested prospectively after collection on all
systems
Test operator: not stated; presume laboratory sta&
Definition of test positivity: not stated; states “testing was performed according to the
manufacturer’s instructions” but no presumptive positives reported
Blinding reported: not stated
Timing of samples: not stated
Study also evaluates [C] GenMar kePlex® SARS-CoV-2 Test (not eligible for this review)
Target condition and reference stan-
dard(s)
Reference standard: RT-PCR; Hologic Panther Fusion SARS-CoV-2 assay, performed ac-
cording to manufacturer's IFU
Definition of non-COVID cases: single RT-PCR
Genetic target(s): 2 regions of ORF1ab; either positive
Samples used: NP swabs; same as for index test
Timing of reference standard: not stated
Blinded to index test: not stated
Incorporated index test: no
Flow and timing Time interval between index and reference tests: not stated in exact terms; delay be-
tween index and reference only for GenMark assay, as 88 samples tested at time of collec-
tion with ePlex then frozen before testing with all other assays.
All participants received same reference standard: yes
Missing data: none reported
Uninterpretable results: 1 specimen with invalid result on ID NOW was excluded from that
dataset
Indeterminate results (index test): none reported; no re-testing conducted
Indeterminate results (reference standard): none reported; no re-testing conducted
Unit of analysis: not stated only refers to samples
Comparative  
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Notes Funding: none stated; study authors thank Cepheid for providing the reagents used
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: Gregory Berry has previously given education seminars for Abbott, Cepheid,
and Hologic, Inc. and has received Honorariums
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclu-
sions?
Unclear    
Did the study avoid inappropriate inclu-
sions?
Yes    
Could the selection of patients have
introduced bias?
  High risk  
Are there concerns that the included
patients and setting do not match the
review question?
    High
DOMAIN 2: Index Test (Antigen tests)
DOMAIN 2: Index Test (Rapid PCR tests)
Were the index test results interpreted
without knowledge of the results of the
reference standard?
Unclear    
If a threshold was used, was it pre-spec-
ified?
Yes    
Could the conduct or interpretation of
the index test have introduced bias?
  Unclear risk  
Are there concerns that the index test,
its conduct, or interpretation differ
from the review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to cor-
rectly classify the target condition?
No    
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Were the reference standard results in-
terpreted without knowledge of the re-
sults of the index tests?
Unclear    
Reference standard does not incorpo-
rate result of index test?
Yes    
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
  High risk  
Are there concerns that the target
condition as defined by the reference
standard does not match the ques-
tion?
    High
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference stan-
dard?
Yes    
Did all patients receive the same refer-
ence standard?
Yes    
Were all patients included in the analy-
sis?
No    
Did all participants receive a reference
standard?
Yes    
Were results presented per patient? Unclear    
Could the patient flow have intro-
duced bias?





Patient Sampling See Zhen 2020 [A] for full study details and QUADAS entries
Patient characteris-
tics and setting
See Zhen 2020 [A] for full study details and QUADAS entries
Index tests Zhen 2020 [B] is the entry for test [B] from the list below, see Zhen 2020 [A] for full study details and QUADAS
entries
Test name:
[A] Xpert® Xpress SARS-CoV-2
[B] ID NOWCOVID-19
(no product codes reported)
Manufacturer: [A] Cepheid, [B] Abbott
Antigen target: [A] N2, E; [B] RdRp
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Antibody: N/A
Test method: rapid PCR
Samples used: NP swabs
Transport media: UTM (various manufacturers)
Sample storage: on collection, stored at 2-8 0C for up to 72 h; after routine testing, stored at −80 0C
88 samples tested using ePlex on collection, then frozen prior to testing with ID NOW, Xpert Xpress and Holog-
ic RT-PCR; 20 samples tested prospectively after collection on all systems
Test operator: not stated; presume laboratory sta&
Definition of test positivity: not stated; states “testing was performed according to the manufacturer’s instruc-
tions” but no presumptive positives reported
Blinding reported: not stated
Timing of samples: not stated




See Zhen 2020 [A] for full study details and QUADAS entries
Flow and timing See Zhen 2020 [A] for full study details and QUADAS entries
Comparative  
Notes Funding: none stated; study authors thank Cepheid for providing the reagents used
Publication status: accepted manuscript
Source: Journal of Clinical Microbioloby
Author COI: Gregory Berry has previously given education seminars for Abbott, Cepheid, and Hologic, Inc. and
has received Honorariums
Zhen 2020 [B]  (Continued)
BAL: bronchoalveolar lavage; CDC: Center for Disease Control; CGIA: colloidal gold immunoassay; COI: conflict of interest; Ct: cycle
threshold; ED: Emergency Department; EUA: emergency use authorisation; FIA: fluorescence immunochromatographic; FN: false
negative; FP: false positive; GLY: Glucose-Lactalbumin-Yeast; HCW: healthcare worker; ICU: intensive care unit; IFU: instructions
for use; IQR: interquartile range; LDT: laboratory-developed test; N/A: not applicable; NAAT: nucleic acids amplification test; NIH:
National Institutes of Health; NOP: naso-oropharyngeal; NP: nasopharyngeal; OP: oropharyngeal; PCR: polymerase chain reaction; PHE:
Public Health England; qRT-PCR: quantitative reverse transcription polymerase chain reaction; RNA: ribonucleic acid; RT-PCR: reverse
transcription polymerase chain reaction; SD: standard deviation; TA: tracheal aspirate; TN: true negative; TP: true positive; UTM: universal
transport medium; UV: ultraviolet; UW: University of Washington; VTM: viral transport medium;
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ai 2020 Ineligible index test
Anahtar 2020 Ineligible index test
Arumugam 2020 Ineligible index test
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Study Reason for exclusion
Baek 2020 Ineligible index test
Barra 2020 Ineligible study design
Basu 2020 Ineligible reference standard
Behrmann 2020 Accuracy data cannot be extracted
Bordi 2020 Ineligible study design
Broughton 2020 Ineligible index test
Callahan 2020 Accuracy data cannot be extracted
Chandler-Brown 2020 Ineligible study design
Colson 2020 Inadequate sample size
Comar 2020 Ineligible reference standard
Crone 2020 Ineligible index test
Curti 2020 Ineligible study design
Ding 2020 Ineligible study design
Dohla 2020 Ineligible index test
Farfan 2020 Ineligible study design
Francis 2020 Ineligible study design
Freire-Paspuel 2020 Ineligible study design
Ganguli 2020 Ineligible population
Giamarellos-Bourboulis 2020 Ineligible study design
Gonzalez-Gonzalez 2020 Ineligible study design
Grant 2020 Ineligible index test
Hass 2020 Ineligible target condition
Hogan 2020a Ineligible index test
Hu 2020 Ineligible index test
Huang 2020 Ineligible index test
Jiang 2020 Ineligible index test
Joung 2020 Ineligible index test
Kalikiri 2020 Ineligible index test
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Study Reason for exclusion
Kim 2019 Ineligible study design
Konrad 2020 Ineligible study design
Kurstjens 2020 Ineligible index test
Lalli 2020 Inadequate sample size
Lamb 2020 Ineligible study design
Lee 2020 Ineligible index test
Lin 2020 Ineligible population
Lowe 2020 Ineligible index test
Lu 2020 Ineligible study design
Lu 2020a Ineligible index test
Mahari 2020 Ineligible study design
Marzinotto 2020 Accuracy data cannot be extracted
McCormick-Baw 2020 Ineligible index test
McRae 2020 Ineligible index test
Mei 2020 Ineligible index test
Noerz 2020 Ineligible index test
Osterdahl 2020 Ineligible index test
Paden 2020 Ineligible study design
Pellanda 2020 Ineligible index test
Pfefferle 2020 Ineligible study design
Seo 2020 Accuracy data cannot be extracted
Smyrlaki 2020 Ineligible index test
St Hilaire 2020 Ineligible index test
Tan 2020 Ineligible study design
Visseaux 2020 Ineligible index test
Wang 2020 Ineligible index test
Wang 2020a Accuracy data cannot be extracted
Wee 2020 Ineligible study design
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Study Reason for exclusion
Xue 2020 Ineligible index test
Yan 2020 Ineligible index test
Yang 2020 Ineligible index test
Yu 2020 Ineligible index test
Yu 2020a Ineligible index test
Zamecnik 2020 Ineligible index test
Zeng 2020 Ineligible study design
Zhang 2020 Ineligible index test
Zhao 2020 Ineligible study design
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 Antigen tests - All 8 1180
2 Antigen tests - high viral load 7 400
3 Antigen tests - low viral load 7 341
4 Molecular tests - all 15 2325
5 Molecular tests - all (before discrepant analysis) 4 1280
6 Molecular tests - all (after discrepant analysis) 4 1280
7 Molecular tests - high viral load 5 151
8 Molecular tests - low viral load 5 142
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Test 1.   Antigen tests - All
 
 
Test 2.   Antigen tests - high viral load
 
 
Test 3.   Antigen tests - low viral load
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Test 4.   Molecular tests - all
 
 
Test 5.   Molecular tests - all (before discrepant analysis)
 
 
Test 6.   Molecular tests - all (aKer discrepant analysis)
 
 
Test 7.   Molecular tests - high viral load
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Test 8.   Molecular tests - low viral load
 
 
A D D I T I O N A L   T A B L E S
 
  Antigen tests Molecular tests
Participants 5 13
Overall sample size Median (IQR) 112 (96 to 198)
  Range 26 to 524
Overall number of SARS-CoV-2
positive samples
Median (IQR) 85 (50 to 119)
  Range 13 to 220
Sample size Median (IQR) 138 (127 to 239) 103 (88 to 172)
  Range 111 to 328 26 to 524
Number of SARS-CoV-2 posi-
tive samples
Median (IQR) 94 (82 to 132) 58 (46 to 96)
  Range 80 to 208 13 to 220
Setting Hospital A & E 2 (40%) 1 (8%)
  Mixed 0 (0%) 3 (31%)
  Unclear 3 (60%) 9 (69%)
Patient group Acute (A&E presentation) 2 (40%) 1 (8%)
  Unclear 3 (60%) 12 (92%)
Study design      
Recruitment structure Single group - sensitivity and specificity 3 (60%) 6 (46%)
  Single group - sensitivity only 0 (0) 2 (15%)
Table 1.   Description of studies 
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  Two or more groups - sensitivity and specificity 2 (40%) 5 (38%)
Reference standard for pres-
ence of SARS-CoV-2
All RT-PCR positive 5 (100%) 13 (100%)
Reference standard for ab-
sence of SARS-CoV-2
COVID suspects (double RT-PCR negative) 1 (20%) 0 (0%)
  COVID suspects (single RT-PCR negative) 4 (80%) 11 (85%)
  Not applicable 0 (0) 2 (15%)
Tests      
Number of tests per study 1 4 (80%) 11 (84.6%)
  2 0 (0) 2 (15.4%)
  4 1 (20%) 0 (0)
Test technology, antigen tests
onlya
Colloidal-gold immunoassay 4 (50%) N/A
  Fluorescent immunoassay 4 (50%) N/A
Sample type Nasal only 0 (0%) 1 (8%)
  Nasopharyngeal only 3 (60%) 6 (46%)
  Nasopharyngeal + oropharyngeal combined 2 (40%) 1 (8%)
  Nasopharyngeal or nasal 0 (0) 3 (23%)
  Nasopharyngeal or oropharyngeal 0 (0) 1 (8%)
  Mixed (3 or more types) 0 (0) 1 (8%)
IQR: interquartile range; RT-PCR: reverse transcriptase polymerase chain reaction
Table 1.   Description of studies  (Continued)










All 8 (5) 1180 762 56.2 (29.5 to 79.8) 99.5 (98.1 to 99.9)
Subgroup analysis by viral load
High viral load 7 (5) 400 400 93.2 (63.6 to 99.1) N/A
Table 2.   Summary of analyses of test accuracy 
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Low viral load 7 (5) 341 341 32.6 (17.5 to 52.6) N/A
Difference (95% CI) −60.6 (−83.0 to −38.2), P <
0.001
N/A
Subgroup analysis by test a
Beijing Savant FIA 1 109 78 16.7 (9.2 to 26.8) 100 (88.8 to 100)
Coris Bioconcept
CGIAb
2 466 226 54.4 (47.9 to 60.8) 99.6 (97.7 to 99.9)
Liming CGIA 1 19 9 0 (0 to 33.6) 90.0 (55.5 to 99.7)
RapiGEN CGIA 1 109 79 62.0 (50.4 to 72.7) 100 (88.4 to 100)
Shenzhen Bioeasy
FIAb
2 238 162 89.5 (83.8 to 93.3) 100 (95.2 to 100)
In-house FIA 1 239 208 67.8 (61.0 to 74.1) 100 (88.8 to 100)
Subgroup analysis by sample type
Nasopharyngeal only 3 705 434 59.4 (50.7 to 67.5) 99.6 (97.4 to 99.9)
Molecular tests
All studies with 2x2
data
13 (11) 2194 1113 95.2 (86.7 to 98.3) 98.9 (97.3 to 99.5)
All studiesc,d 15 (13) 1244 1244 95.5 (88.5 to 98.4) N/A
Sensitivity analysis before and after discrepant analysis
Before 4 1280 536 98.2 (87.0 to 99.8) 97.8 (94.8 to 99.1)
After 4 1280 547 99.5 (79.9 to 100) 99.6 (98.7 to 99.9)
Subgroup analyses by viral load
High viral loadb 5 (4) 151 151 100 (97.5 to 100) N/A
Low viral load 5 (4) 142 142 93.3 (46.7 to 99.6) N/A
Subgroup analyses by test a
Abbott – ID NOW 5 1003 496 76.8 (72.9 to 80.3) 99.6 (98.4 to 99.9)
Cepheid – Xpert
Xpress
6 919 479 99.4 (98.0 to 99.8) 96.8 (90.6 to 99.0)
Difference (95% CI) 22.6 (18.8 to 26.3), P < 0.001 −2.8 (−6.4 to 0.8), P =
0.13
Mesa Biotech – Accu-
la
1 100 50 68.0 (53.3 to 80.5) 100 (92.9 to 100)
Table 2.   Summary of analyses of test accuracy  (Continued)
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DRW – SAMBA II 1 172 88 98.9 (93.8 to 100) 96.4 (89.9 to 99.3)
Direct comparisons by test
Abbott – ID NOWa,b 2 220 145 79.3 (71.8 to 85.6) 100 (95.2 to 100)
Cepheid – Xpert
Xpressa,b
2 221 146 98.6 (95.1 to 99.8) 97.3 (90.7 to 99.7)
Difference (95% CI)e 19.3 (12.5 to 26.2), P < 0.001 −2.7 (−6.3 to 1.0), P =
0.15
Sample type          
Nasopharyngeal on-
lyc
6 (5) 600 343 87.1 (71.6 to 94.7) 100 (98.6 to 100)
CGIA: colloidal gold immunoassay; CI: confidence intervals; FIA: fluorescent immunoassay; DRW: Diagnostics for the Real World
Table 2.   Summary of analyses of test accuracy  (Continued)
aSee Appendix 9 for details of product codes, where available (these were not necessarily reported in studies but we obtained them from
manufacturer instructions for use documents).
b2x2 tables combined prior to calculating estimates.
cSeparate pooling of sensitivity and/or specificity.
dThis includes two studies that only include COVID-19 positive cases.
eTwo-sample test of proportions.
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3 FPs (reclassified as TP), all border-
line positive for ≥ 1 target gene on ei-
ther RT-PCR test








Not stated Same RT-
PCR
Same 2 → 0 47 no-
retest
1 FP reclassified
as TN with repeat
sampling
1 FP not re-tested
1 FP reclassified as TP
1 FP reclassified as TN


























































11 → 3 1 → 0 None reported 1 FN re-classified as TN (inconclusive
positive on Quest assay; negative on
CDC assay)
3 FP remained as FP (2 negative on
NY assay, 1 negative on Charité Vi-
rologie assay; all confirmed negative
with Hologic Panther Fusion)
8 FP re-classified as TP (all negative
on Charité Virologie assay; positive









ORF1, E Same RT-
PCR
Same 1 → 0 0 1 FP reclassified
as TN (was initial-
ly E gene nega-
tive and low pos-
1 FP 'repeatedly negative' on RT-PCR
re-test (re-classified as TN based on
index re-test)

























































































































































































itive for N2; neg-
ative for both tar-
gets on re-test)





















E gene N/A N/A 0 16 Yes;































N1, N2 Abbott Re-
alTime
N, RdRp 0 → 0 25 → 31 None reported All samples tested with both RT-PCR
assays
25 FN remained as FN (2 were incon-
clusive but considered positive on
CDC assay, confirmed positive with
Abbott RealTime assay)
6 TN reclassified as FN (negative on
CDC assay, confirmed positive with
Abbott RealTime assay)
All 8 discordant results between the
two RT-PCR's were confirmed SARS-
















Same 0 → 2 0 None reported
1 presumptive
positive consid-
ered TP by review
team
2 TP samples (both positive on only
one target; 1 presumptive positive (E
positive) and 1 positive (N2 positive))
re-classified as FP; both considered

































































































































































































SARS-CoV-2 negative on RT-PCR re-
test
*authors note that viral loads were
at the limit of detection for Xpert
Xpress and that multiple freeze-thaw
steps of samples could have had a
significant impact on detection.
CDC: center for disease control; EUA: emergency use authorisation; FN: false negative; FP: false positive; PHE: Public Health England; RT-PCR: reverse transcriptase poly-
merase chain reaction; RUO: research use only; TN: true negative; TP: true positive
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A P P E N D I C E S
Appendix 1. Summary of World Health Organization and Chinese National Health Commission Guidelines for the
diagnosis of SARS-CoV-2
Table A: World Health Organization guidelines for the diagnosis of SARS-CoV-2a





























































10-30 January: no documentation to de-
fine at this time (before first date of glob-
al guidelines)
31 January onwards: a confirmed case is
a person with laboratory confirmation of
COVID-19 infection, irrespective of clinical
signs and symptoms.
No prescribed test in laboratory guide-
lines, suggested tests from 10 January
include broad coronavirus RT-PCR (with
sequencing of precise virus in test posi-
tives), whole genome sequencing, broad
coronavirus serology on paired samples,
microscopy, culture
(Lab 10 January). Four suggested tests
from 17 January: broad coronavirus RT-
PCR (with sequencing of precise virus in
test positives), NAAT for SARS-CoV-2 when
it becomes available, whole genome se-
quencing, and broad coronavirus serolo-
gy on paired samples.
States that once specific NAAT assays
are developed and validated, confirma-
tion will be based on specific detection of

































A person with laboratory confirmation of
COVID-19 infection, irrespective of clinical
signs and symptoms (global 31 January,
27 February, 20 March)
Laboratory confirmation of cases by NAAT
specific to SAR-CoV-2 such as real-time
reverse-transcription polymerase chain
reaction (rRT-PCR) with confirmation by
nucleic acid sequencing when necessary.
The viral genes targeted so far include the






























there is a strong
epidemiologi-
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In areas with no known COVID-19 virus
circulation confirmation requires:
• NAAT positive for at least two different
targets on the COVID-19 virus genome,
of which at least one target is preferably
specific for COVID-19 virus (or SARS-like
coronavirus) using a validated assay;
OR
• NAAT-positive result for betacoron-
avirus, and COVID-19 virus identified
by sequencing partial/whole genome
of virus (sequence target larger or dif-
ferent from the amplicon probed in the
NAAT assay).
Discordant results should be resampled.
In areas where COVID-19 virus is wide-
ly spread a simpler algorithm might be




























NAAT: nucleic acids amplification test; RT-PCR: reverse transcription polymerase chain reaction.
  (Continued)
 
aSource data from Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, World Health
Organization. 10 January, 17 January, 2 March, 19 March, 21 March 2020 (WHO 2020a), and Global surveillance for COVID-19 caused by
human infection with COVID-19 virus, interim guidance, 31 January, 27 February, and 20 March 2020 (WHO 2020b).
Table B: Summary of Chinese National Health Commission guidelines for diagnosis and treatment for novel coronavirus
pneumonia (trial versions 1-7)
 
Dates in effect Definition of confirmed case Definition of con-
firmed non-case




Cases (not confirmed cases) de-
fined as virus genome highly ho-
mologous to coronaviruses
Not defined Observation cases: defined as
combination of exposure in Wuhan
and symptoms focused on pneu-





2, 3, 4, 5, 5 re-
vised, and 6)
Suspect cases with either
• real-time fluorescent RT-PCR
indicates positive for new
coronavirus nucleic acid; OR
• viral gene sequence is high-
ly homologous to known new
coronaviruses.
Suspect cases can




tests taken at least
24 hours apart.
Suspect cases: combination of ex-
posure (such as residence in/trav-
el to Wuhan or exposure to a con-
firmed case within 14 days of on-
set) AND clinical features (such
as symptoms: fever, respiratory
symptoms, and tests: chest imag-
ing, white blood cell and lympho-





Suspect cases with either
• real-time fluorescent RT-PCR
indicates positive for new
coronavirus nucleic acid; OR
Suspect cases can
be ruled out after
2 negative NAATs,
taken at least 24
hours apart, and
the NCP virus-spe-
Suspect cases: combination of ex-
posure (such as residence in/trav-
el to Wuhan or exposure to a con-
firmed case within 14 days of on-
set) AND clinical features (such
as symptoms: fever, respiratory
Part of definition
of cases and con-
firmed non-cases
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• viral gene sequence is high-
ly homologous to known new
coronaviruses. OR
• NCP virus-specific IgM and
IgG are detectable in serum;
NCP virus-specific IgG is de-
tectable or reaches a titration
of at least 4-fold increase dur-
ing convalescence compared
with the acute phase.
cific IgM and IgG
are negative after
7 days from onset.
symptoms, and tests: chest imag-
ing, white blood cell and lympho-
cyte count).
NAAT: nucleic acids amplification test; NCP: novel coronavirus pneumonia; RT-PCR: reverse transcription polymerase chain reaction;
Source: Table from Cheng 2020
  (Continued)
 




WHO ICTRP Health topic: 2019-nCov / COVID-19
PubMed (("2019 nCoV"[tiab] OR 2019nCoV[tiab] OR "2019 novel coronavirus"[tiab] OR "COVID 19"[tiab]
OR COVID19[tiab] OR "new coronavirus"[tiab] OR "novel coronavirus"[tiab] OR "novel coro-
na virus"[tiab] OR "SARS CoV-2"[tiab] OR (Wuhan[tiab] AND (coronavirus[tiab] OR "corona
virus"[tiab])) OR "COVID-19"[Supplementary Concept] OR "severe acute respiratory syndrome
coronavirus 2"[Supplementary Concept]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH
Terms])) NOT (editorial[pt] OR comment[pt] OR letter[pt] OR newspaper article[pt])
 
 
aAutomatic term mapping links results for 2019-nCoV, 2019 novel coronavirus, SARS-CoV-2, severe acute respiratory syndrome coronavirus
2.
Appendix 3. Living search from the University of Bern
The following information is taken from the university of Bern website (see: ispmbern.github.io/covid-19/living-review/
collectingdata.html).
The register is updated daily and CSV file downloads are made available.
1 April 2020
From 1 April 2020, we will retrieve the curated BioRxiv/MedRxiv dataset (connect.medrxiv.org/relate/content/181).
26 to 31 March 2020
MEDLINE: (\"Wuhan coronavirus\" [Supplementary Concept] OR \"COVID-19\" OR \"2019 ncov\"[tiab] OR ((\"novel coronavirus\"[tiab] OR
\"new coronavirus\"[tiab]) AND (wuhan[tiab] OR 2019[tiab])) OR 2019-nCoV[All Fields] OR (wuhan[tiab] AND coronavirus[tiab])))))
Embase: (nCoV or 2019-nCoV or ((new or novel or wuhan) adj3 coronavirus) or covid19 or covid-19 or SARS-CoV-2).mp.
BioRxiv/MedRxiv: ncov or corona or wuhan or COVID or SARS-CoV-2
With the kind support of the Public Health & Primary Care Library PHC (www.unibe.ch/university/services/university_library/
faculty_libraries/medicine/public_health_amp_primary_care_library_phc/index_eng.html), and following guidance of the Medical
Library Association (www.mlanet.org/p/cm/ld/fid=1713).
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1 January 2020 to 25 March 2020
MEDLINE: ("Wuhan coronavirus" [Supplementary Concept] OR "COVID-19" OR "2019 ncov"[tiab] OR (("novel coronavirus"[tiab] OR "new
coronavirus"[tiab]) AND (wuhan[tiab] OR 2019[tiab])) OR 2019-nCoV[All Fields] OR (wuhan[tiab] AND coronavirus[tiab])))))
Embase: ncov OR (wuhan AND corona) OR COVID
BioRxiv/MedRxiv: ncov or corona or wuhan or COVID
Appendix 4. CDC Library, COVID-19 Research Articles Downloadable Database
Embase records from the Stephen B. Thacker CDC Library, COVID-19 Research articles Downloadable database
Records were obtained by the CDC library by searching Embase through Ovid using the following search strategy.
 
Source Strategy
Embase coronavir* OR corona virus* OR betacoronavir* OR covid19 OR covid 19 OR nCoV OR novel CoV OR
CoV 2 OR CoV2 OR sarscov2 OR 2019nCoV OR wuhan virus*).mp. OR ((wuhan OR hubei OR huanan)
AND (severe acute respiratory OR pneumonia*) AND outbreak*).mp. OR Coronavirus infection/ OR
coronavirinae/ OR exp betacoronavirus/
Limits: 2020-
OR
(novel coronavir* OR novel corona virus* OR covid19 OR covid 19 OR nCoV OR novel CoV OR CoV 2
OR CoV2 OR sarscov2 OR 2019nCoV OR wuhan virus*).mp. OR ((wuhan OR hubei OR huanan) AND
(severe acute respiratory OR pneumonia*) AND outbreak*).mp. OR ((wuhan OR hubei OR huanan)
















A1 Purpose B1 Setting D1.1 Test name (please include
product code if reported)
E1 Reference stan-














clude name of insti-
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targets
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  B8 Comment D1.8 Samples used (include
who collected by)




D1.8.1 Transport media (vol-
ume and manufacturer detail)
E8 Timing of refer-
ence standard
   
  C1.1 Group name D1.8.2 Sample storage and
timing of test
E9 Was it blind to in-
dex test?
   
  C1.2 Source and
time
D1.9 Who applied the test (in-
clude reported training/e)?
E10 Did it incorpo-
rate index test?
   
  C1.3 Characteristics D1.10 How was positive de-
fined?
E11 Comment    
  C2.1 Group name D1.11 Blinded to reference
standard
     
  C2.2 Source and
time
D1.12 Threshold predefined      
  C2.3 Characteristics D1.13 Comment      
CoI: conflict of interest; POC: point of care; RT-PCR: reverse transcription polymerase chain reaction
  (Continued)
 
Appendix 6. Criteria for assessment of study quality (QUADAS-2)
 
DOMAIN: Participant selection
Was a consecutive or random
sample of patients enrolled?
This will be similar for all index tests, target conditions, and populations.
Yes: if a study explicitly stated that all participants within a certain time frame were included; that
this was done consecutively; or that a random selection was done.
No: if it was clear that a different selection procedure was employed; for example, selection based
on clinician's preference, or based on institutions, or based on result of RT-PCR
Unclear: if the selection procedure was not clear or not reported
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Was a case-control design
avoided?
This will be similar for all index tests, target conditions, and populations.
Yes: if a study explicitly stated that all participants came from the same group of (suspected) pa-
tients.
No: if it was clear that a different selection procedure was employed for the participants depending
on their COVID-19 status or SARS-CoV-2 infection status; or if only participants with SARS-CoV-2 in-
fection were included
Unclear: if the selection procedure was not clear or not reported.
Did the study avoid inappro-
priate exclusions?
Studies may have excluded patients, or selected patients in such a way that they avoided including
those who were difficult to diagnose or likely to be borderline. Although the inclusion and exclu-
sion criteria will be different for the different index tests, inappropriate exclusions and inclusions
will be similar for all index tests: for example, only elderly patients excluded, or children (as sam-
pling may be more difficult). This needs to be addressed on a case-by-case basis.
Yes: if a high proportion of eligible patients was included without clear selection.
No: if a high proportion of eligible patients was excluded without providing a reason; if, in a retro-
spective study, participants without index test or reference standard results were excluded.
Unclear: if the exclusion criteria were not reported.
Did the study avoid inappro-
priate inclusions?
Some laboratory studies may have intentionally included groups of patients in whom the accura-
cy was likely to differ, such as those with particularly low or high viral loads, or who had other dis-
eases, such that the sample over-represented these groups. This needs to be addressed on a case-
by-case basis.
Yes: if samples included were likely to be representative of the spectrum of disease.
No: if the study oversampled patients with particular characteristics likely to affect estimates of ac-
curacy.
Unclear: if the exclusion criteria were not reported.
Could the selection of pa-
tients have introduced bias?
High: if one or more signalling questions were answered with no, as any deviation from the selec-
tion process may lead to bias.
Low: if all signalling questions were answered with yes.
Unclear: all other instances
Is there concern that the in-
cluded participants do not
match the review question?
High: for two-group studies that included healthy or other disease controls, whether pre-pandemic
or contemporaneous; studies that only included people with COVID-19 (whether RT-PCR-confirmed
only, participants meeting official guideline criteria);
Low: for single-group studies recruiting participants with signs and symptoms of COVID-19; or for
two-group studies where control groups suspected of COVID-19 were separately recruited.
Unclear: if a description about the participants was lacking.
DOMAIN: Index tests
Were the index test results
interpreted without knowl-
edge of the results of the ref-
erence standard?
Yes: if blinding was explicitly stated or index test was recorded before the results from the refer-
ence standard were available.
No: if it was explicitly stated that the index test results were interpreted with knowledge of the re-
sults of the reference standard.
Unclear: if blinding was unclearly reported.
  (Continued)
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If a threshold was used, was
it prespecified?
Yes: if the test was dichotomous by nature, or if the threshold was stated in the methods section, or
if study authors stated that the threshold as recommended by the manufacturer was used.
No: if a receiver operating characteristic curve was drawn or multiple threshold reported in the re-
sults section; and the final result was based on one of these thresholds.
Unclear: if threshold selection was not clearly reported.
Could the conduct or inter-
pretation of the index test
have introduced bias?
High: if one or more signalling questions were answered with no, as even in a laboratory situation
knowledge of the reference standard may lead to bias.
Low: if all signalling questions were answered with yes.
Unclear: all other instances
Is there concern that the in-
dex test, its conduct, or in-
terpretation differ from the
review question?
For all test types, if index test is 'in-house' or not commercially available, then state 'High'.
If any test procedures used in the study diverged from IFU ((use of VTM, or testing outwith stated
time limit), also state High
If testing carried out in centralised laboratory and not near patient then state High.
Evaluations that withheld the name of the test, or that used mixed sample types or did not report
the evaluation setting, state Unclear
If samples used and any sample processing steps are in accordance with test IFU, or if study de-
scribes conducting the test according to the manufacturer's protocol, state Low
DOMAIN: Reference standard
Is the reference standard
likely to correctly classify
the target condition?
We will define acceptable reference standards using a consensus process once the list of reference
standards that have been used has been obtained from the eligible studies.
For COVID-19 cases
Yes: RT-PCR; confirmed or suspected case using official criteria (WHO, CDC) or a clearly set out com-
bination of signs/symptoms/exposure
No: RT-PCR not used, or if inadequate combination of clinical characteristics used in PCR-nega-
tives, e.g. computed tomography alone
Unclear: if definition of COVID-19 was not reported
For absence of COVID-19
Yes: if at least 2 negative RT-PCR results reported if suspected COVID-19 based on signs/symptoms;
single negative RT-PCR test for asymptomatic contacts or contemporaneous controls with no clini-
cal suspicion of COVID-19; only pre-pandemic sources of control samples used.
No: single RT-PCR or number of negative RT-PCRs not reported for COVID-19 suspects; no RT-PCR
reported (untested) for asymptomatic contacts or contemporaneous controls
Unclear: if timing of control samples (pre-pandemic or contemporaneous) was not reported
Were the reference standard
results interpreted without
knowledge of the results of
the index test?
Yes: if it was explicitly stated that the reference standard results were interpreted without knowl-
edge of the results of the index test, or if the result of the index test was obtained after the refer-
ence standard.
No: if it was explicitly stated that the reference standard results were interpreted with knowledge
of the results of the index test or if the index test was used to make the final diagnosis.
Unclear: if blinding was unclearly reported.
Did the definition of the ref-
erence standard incorpo-
rate results from the index
test(s)?
Yes: if results from the index test were a component of the reference standard definition.
No: if the reference standard did not incorporate the index standard test.
  (Continued)
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Unclear: if it was unclear whether the results of the index test formed part of the reference stan-
dard.
Could the conduct or inter-
pretation of the reference
standard have introduced
bias?
High: if one or more signalling questions were answered with no.
Low: if all signalling questions were answered with yes.
Unclear: all other instances
Is there concern that the tar-
get condition as defined by
the reference standard does
not match the review ques-
tion?
Applicability was judged primarily on the definition of disease-positive.
High: if RT-PCR alone used to define cases
Low: if clinical criteria, including RT-PCR, were used to define cases, regardless of whether official
criteria were used, as long as the criteria were explicitly described.
Unclear: if definition of COVID-19 cases was not provided, including if some clinically diagnosed
cases were included but the clinical criteria used were not described.
DOMAIN: Flow and timing
Was there an appropriate in-
terval between index test
and reference standard?
Yes: if same swab used, or swabs obtained at same time regardless of freezing (which is covered
under index applicability)
No: if different samples used with more than 24 hours between collection times
Unclear: if can't tell
Did all participants receive
the same reference stan-
dard?
Yes: if all participants received the same reference standard (clearly no differential verification).
No: if (part of) the index test-positives or index test-negatives received a different reference stan-
dard.
Unclear: if it was not reported
Were all participants includ-
ed in the analysis?
Yes: if it is clear that all eligible participants were included in the analyses.
No: if after the inclusion/exclusion process, participants were removed from the analyses for dif-
ferent reasons: no reference standard done, no index test done, intermediate results of both index
test or reference standard, indeterminate results of both index test or reference standard, samples
unusable.
Unclear: if it is not possible to determine whether all participants were included (e.g. from a STARD-
style participant flow diagram)
Did all participants receive a
reference standard?
Yes: if all participants received a reference standard (clearly no partial verification).
No: if only (part of) the index test positives or index test negatives received the complete reference
standard.
Unclear: if it was not reported
Were results presented per
participant?
Yes: if either only one sample per participant (regardless of disaggregation of results over time), or
if multiple samples per participant but results are disaggregated by time period (at least week by
week)
No: if multiple samples per participant and results are not disaggregated by time period
Unclear: if it is not possible to tell whether results presented are per participant or per sample
Could the participantflow
have introduced bias?
High: if one or more signalling questions were answered with no.
Low: if all signalling questions were answered with yes.
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Unclear: all other instances
CDC: Centers for Disease Control; ICU: intensive care unit; IFU: instructions for use; RT-PCR: real-time polymerase chain reaction;




















































Threshold < 40 Ct;















into the reference stan-








































ed within a few
hours
4 samples in cobas VTM
gave invalid results so all




Index: control lines "barely





































4. E gene and ORF1-
ab
As for index test;
respiratory spec-
imens (322 NP
swabs, 4 NP aspi-
rate and 2 BAL)
Timing of refer-
ence: analysed





Index: weak T lines consid-
ered positive
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Threshold ≤ 40 Ct
Target: not stated
As for index































































As for index test;
NOP swabs
Timing of refer-
ence: as for in-
dex test; median








2 invalid results in 2 tests




tion of the Savant assay
(using manufacturer-sup-
plied UV torch) was report-
edly difficult under day-
light conditions; manufac-
turer's fluorescence read-






































tested with second RT-
PCR, including 3 FP and 1
FN (see Table 3) assays
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er range of vi-
ral load (E tar-











Target: E gene (un-
clear if other genet-
ic targets as well)














itive on reference were
tested by in-house assay
















EDs (n = 3)
or urgent
care cen-
tres (n = 2)
USA
(Not stated)
Not stated RT-PCR (Abbott Re-
alTime SARS-CoV-2
(ACOV) assay per-
formed on the Ab-
bott m2000 system
(Abbott Molecular















Reference: 2 initial FPs had
























Not stated RT-PCR (in-house
SHC assay )
Target: E gene













3 invalid results were re-
tested; 1 positive and 2
negative
Reference: none reported
Index: 1 known RT-PCR-
positive sample that
showed a faint positive
test line was re-tested and
again showed the same


































if 1 of 2 targets de-
tected - presume at
<40 Ct
Target: NI, N2 genes





to index test: all
testing conduct-
ed within 72 h
None reported; addition-
al data reported compar-




results (i.e. 1 genetic tar-
get detected) considered
positive due to the high
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specificity of all assays
and limited cross-reactiv-
ity seen for SARS-CoV-2
primer sets

















































kits used at differ-
ent sites)


































1. N (N1, N2) gene
2. N (N1, N3) gene
3. S, E genes
4. RdRp, E, N genes
5. RdRp, E, N genes
6. RdRp gene
7. RdRp, N genes
8. ORF1ab, S genes
As for index test
Timing of refer-















time, within 2 h
by the index test)
4 Xpert Xpress test results
were lost permanently
due to a single instrument
computer malfunction
and 1 invalid result exclud-
ed
1 Xpert Xpress test was in-




inconclusive results by a
test, and those with dis-
crepant results between
index and the RT-PCR tests
were analysed by a third
RT-PCR method (see Table
3).
12 specimens (8 NPS, 4
NPS/OPS) were inconclu-
sive and considered posi-
tive for data analysis pur-
poses in the study. 1 NPS
specimen was inconclu-
sive by the Quest SARS-
CoV-2 rRT-PCR test and
negative by the Xpert test.
This specimen was nega-
tive by a tie-breaker NAAT.
Index: presumptive posi-
tive results on index test
were not reanalysed by
the index test, but all dis-
crepant results were re-
analysed by a third RT-PCR
method
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CDC EUA and NY RT-
PCR
Target: not stated
As for index test
Timing of refer-






































































methods used in all
samples)







required Ct <40 for
both targets; neg-
ative if neither tar-
get detected and
positive amplifica-
tion curve for con-
trol (RP) gene; in-
conclusive if only
one target detected




detected or not de-
tected;
Target:





index test: all 3
tests conduct-




2 results were invalid on ID
Now and were not retest-
ed (excluded)
Reference: discordant re-
sults on RT-PCR had record
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Not stated RT-PCR (Roche
cobas SARS-CoV-2





















Reference: single FP was
retested on RT-PCR and
found to be repeatedly
negative
Index: single FP was








































Target: N1 and N2
genes
As for index test
Timing of refer-








ed only 1/2 targets for 2
samples (both considered
positive and diagnosed as
positive on original sam-
ple testing); both were

























































ed, all Ct values <
37 on both target
genes
Target: ORF1 a/b, E-
gene
As for index test
Timing of refer-









Index: 1 sample was a pre-
sumptive positive based
on detection of E-gene tar-
get but not the N2 target
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of E gene or
RdRp on RT-






























3. RIVM Lab: start-
ed with E-gene
and RdRp-gene
and at the be-
ginning of April




As for index test
Timing of refer-












the FN and presumptive
positive samples with RT-
PCR (see Table 3); Index:
1 sample was positive on-
ly on N2 gene (considered
negative according to IFU)
and one was positive only
on E gene (considered pre-
sumptive positive, requir-
ing re-testing according to
IFU). Both samples were








































Target: 2 regions of
ORF1ab; either pos-
itive



















1 specimen with invalid re-




Index: none reported; no
re-testing conducted
BAL: bronchoalveolar lavage; CDC: Centers for Disease Control; Ct: cycle threshold; ED: emergency department; EUA: emergency use
authorisation; FN: false negative; FP: false positive; ICU: intensive care unit; IFU: instructions for use; IQR: interquartile range; NAAT:
nucleic acids amplification test; NOP: naso-oropharyngeal; NP: nasopharyngeal; OP: oropharyngeal; PHE: Public Health England;
qRT-PCR: quantitative reverse transcription polymerase chain reaction; RT-PCR: reverse transcription polymerase chain reaction;
UV: ultraviolet; UW: University of Washington; VTM: viral transport medium
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Appendix 8. Summary index test details
 




Sample details Test operator
Test threshold
Antigen tests







Samples tested: NP in saline
Timing of sampling: not stated















Samples tested: NP in VTM
Timing of sampling: not stated
Timing of test: not stated (soon
after collection)




Threshold: as per manu-
facturer









Samples tested: NP in VTM
Timing of sampling: not stated





ing at the Test line position
(T)
Porte 2020 Diagnostic Kit for 2019-
Novel Coronavirus (2019-










Samples tested: NP + OP in VTM
Timing of sampling: not stated
Timing of test: not described
Storage: not reported
Laboratory technician
Threshold: as per manu-
facturer
Weitzel 2020 [A] [A] Biocredit COVID-19 Ag
One Step SARS-CoV-2 Anti-








Samples tested: NP + OP in VTM
Timing of sampling: not stated
Timing of test: not described
Storage: not reported
Single trained laborato-
ry technician under BSL2
cabinet; visual outputs
read by 2 independent ob-
servers with referral to
third if needed
Threshold: as per manu-
facturer
Weitzel 2020 [B] [B] COVID-19 Anti-
gen Rapid Test Device
StrongStep COVID-19 Anti-
gen Test (Liming Bio-Prod-
ucts Co., Jiangsu, China)
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Weitzel 2020 [C] [C] Huaketai New Coron-
avirus (SARS-CoV-2) N Pro-






HKT-050; Lot No. 20031501
FIA
N protein
  As above plus test re-
quired use of manufactur-
er supplied UV torch due
to unavailability of reader
device in Chile
Weitzel 2020 [D] [D] Diagnostic Kit for 2019-
Novel Coronavirus (2019-










Assennato 2020 SAMBA II SARS-CoV-2 Test
(Diagnostics for the Real
World)




Samples tested: NP + OP in VTM
Timing of sampling: not stated




Threshold: as per man-
ufacturer; either target
present
Broder 2020 GeneXpert Xpress SARS-
CoV-2 assay (Cepheid Inc)





Timing of sampling: not stated





Threshold: as per manu-
facturer
Harrington 2020 ID Now COVID-19 assay
(Abbott Laboratories)
Product code not reported
Isothermal PCR
Not stated
Samples tested: NP (no VTM)
Timing of sampling: not stated




(urgent care centres); lab-
oratory personnel at each
separate location (EDs)
- 2 sites reportedly expe-
rienced users of ID Now
(one ED and 1 urgent care
centre) and 3 sites re-
ceived training)
Threshold: as per manu-
facturer
Hogan 2020 Accula SARS-CoV-2 POCT
(Mesa Biotech, Inc., San
Diego, CA)
Product code not reported
RT-PCR
N gene
Samples tested: NP in VTM or
saline
Timing of sampling: not stated
Timing of test: not stated (possi-
bly soon after collection)
Not stated; performed at
the SHC Clinical Virology
Laboratory
Threshold: as per manu-
facturer
  (Continued)
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[A] Xpert Xpress (Cepheid)
Study also evaluate 4 addi-
tional tests not eligible for
this review
Product code not reported
RT-PCR
[A] E, N2 genes
Samples tested: NP in VTM
Timing of sampling: not stated
Timing of test: < 72 h




Threshold: any 1 of 2 tar-
gets detected was consid-
ered positive for all assays;
Xpert Xpress data extract-
ed as per IFU definition
(positive = both targets or
N gene positive)
Loeffelholz 2020 Cepheid Xpert Xpress
SARS-CoV-2 (RUO version)
(Cepheid Europe)











Timing of sampling: not stated
Timing of test: not stated; ex-
cept 1 site < 2 h (n = 21)
Storage: stored at −80 °C; except
1 site tested in real time (n = 21)
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer (if both targets
are detected, or, if only
N2 is detected, the test
reports a positive result.
If only the E target is de-
tected the test reports a
presumptive positive re-
sult because this target is
shared among some mem-
bers of the sarbecovirus
subgenus of coronavirus-
es)
Mitchell 2020 ID NOW COVID-19 (Abbott,
Chicago, USA)
Product code not reported
Isothermal PCR
Not stated
Samples tested: NP in VTM
Timing of sampling: not stated
Timing of test: not stated
Storage: stored at −80 ℃
Certified laboratory per-
sonnel
Threshold: as per manu-
facturer
Moore 2020 ID NOW (Abbott Laborato-
ries)
Product code not reported
Isothermal PCR
RdRp gene
Samples tested: NP in VTM
Timing of sampling: not stated
Timing of test: < 72 h from col-
lection
Storage: none, or stored at 4 °C
(if testing could not be complet-
ed on the same day)
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer
Moran 2020 Xpert Xpress SARS-CoV-2
assay (Cepheid, Sunny-
vale, CA)
Product code not reported
RT-PCR
E, N (N2 region)
genes
Samples tested: NP or nasal
Timing of sampling: not stated




Threshold: as per manu-
facturer
Rhoads 2020 [A] ID Now (Abbott; Chica-
go, USA)




Samples tested: NP in VTM or
nasal in saline
Timing of sampling: not stated
Timing of test: not stated
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer
  (Continued)
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[B] Simplexa (Diasorin;
Saluggia, Italy); not eligi-




[A] ID Now (Abbott)





[B] Xpert Xpress (Cepheid)
Product code not reported
RT-PCR
[B] N2, E genes
Samples tested: NP in VTM or
nasal in saline
Timing of sampling: not stated
Timing of test: within 48 h col-
lection
Storage: stored at 4 °C
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer
Wolters 2020 Xpert Xpress SARS-CoV-2
(Cepheid Europe)






Samples tested: NP or OP in
VTM or GLY
Timing of sampling: not stated
Timing of test: not stated
Storage: stored at −80 ℃
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer: E-gene only posi-
tive specimens considered
‘SARS-CoV-2 presump-
tive positive’ and require
retesting, N2 only posi-
tives deemed positive
Zhen 2020 [A] [A] Xpert Xpress SARS-
CoV-2 (Cepheid)
Product code not reported
RT- PCR
[A] N2, E genes
Zhen 2020 [B] [B] ID NOW COVID-19 (Ab-
bott)
Product code not reported
Also evaluates
[C] ePlex SARS-CoV-2 Test




Samples tested: NP in VTM
Timing of sampling: not stated
Timing of test: for routine test-
ing up to 72 h; 20 samples test-
ed prospectively after collection
on all systems
Storage: for routine testing
(ePlex) stored at 2-8 0C; then
stored at −80 0C (ID Now, Xpert
Xpress and Hologic RT-PCR);
20 samples tested prospectively
after collection on all systems
Not stated; presumably
lab sta&
Threshold: as per manu-
facturer
CGIA: colloidal gold immunoassay; ED: emergency department; EUA: Emergency Use Authorisation; FIA: fluorescent immunoassay;
GLY: gelatin-lactalbumin-yeast; IFU: instructions for use; NP: nasopharyngeal; OP: oropharyngeal; PCR: polymerase chain reaction;
RT-PCR: reverse transcription polymerase chain reaction; SD: standard deviation; UV: ultraviolet; VTM: viral transport medium
  (Continued)
 
Appendix 9. Index test details from manufacturer instructions for use documents
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Paper strips in a bot-
tle with desiccant; LY-
S dilution bu&er (3.5
mL or 15 mL; tubes
and stoppers);


















Visual; read through collec-
tion tube.
Control line only (negative),
T line (with or without con-






























or sleeve up to
72 h at 15-30 °C,
or 2-8 °C before
processing
Visual; 2 coloured bands for
positive; control band only












diluent tube and fil-
ter cap, swab for NP
collection;
1-40 °C







°C for up to 12
h, or −20 °C for
up to 24 h
Visual; control line only
(negative), control and test








































at 2-8 °C for ≤
24 h; or store








positive if both detection
line and control line detect
a fluorescent signal, and the
detection line detection val-
ue is ≥ 0.005 ng/mL; nega-
tive if fluorescent signal on
control line only; invalid if
no fluorescent signal, or sig-
nal only on test line
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(with 2 sealed reac-




of the eluted sam-
ple to the test base,
positive and nega-
tive control swabs;






























up to 2 h. If
longer then
store at 2-8 °C





played on the instrument
screen as positive, negative
or presence or absence of







































up to 8 h or re-
frigerate (2–8




tive (N2+ and E+, or N2+ on-
ly), presumptive positive
(E+ only), negative (both






















la or Silaris dock re-























up to 24 h or re-
frigerated (2-8b
°C) and tested




stored for up to
1 week at −20
°C
Visually interpretation
(shown as blue test and
control lines on exterior of
test cassette): positive (any
test line at T position, with
or without control line C,
but with no negative con-
trol line), negative (control
line only with no negative
control line), invalid (ap-
pearance of negative con-














Each test set con-
tains 4 cartridges for
extraction, ampli-
fication and detec-
tion of the amplifi-
cation products, 2
ml SCoV bu&er, fixed
volume pipette, 300

















Store at 2-30 °C






stored on the connected
tablet -
Tablet module result: nega-
tive, positive, invalid, halt-
ed, read failure or no re-
sults;
Visual reading of test strip:
internal control line only
(Negative), ≥ 1 of 2 test lines
(ORF and or N lines) with or
  (Continued)
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tion tube and sam-
ple card; SAMBA II
Assay Module and
Tablet module both
required to run the
test;
2-37°C
without internal control line
(positive), no lines (invalid);
other combinations possi-
ble in rare cases
ASAP: as soon as possible; CGIA: colloidal gold immunoassay; IFU: instructions for use; NP: nasopharyngeal; NPS: nasopharyngeal
swab; OP: oropharyngeal; RNA: ribonucleic acid; RT-PCR: reverse transcription polymerase chain reaction; UVM: universal transfer
medium; VTM: viral transport medium
aThe reported product codes are as reported in the instructions for use documents and may diverge from those evaluated in the in-
cluded studies (product codes were reported in only two of 18 studies).
  (Continued)
 
Appendix 10. Study-level assessments of study quality
Figure 8
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Figure 8.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study
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Appendix 11. Planned heterogeneity investigations
 






Study design      
Antigen tests      
Single group – sensitivity and specificity 3 (3) 434 271
Two or more groups – sensitivity and specificity 5 (2) 328 147
Rapid molecular tests      
Single group – sensitivity and specificity 6 (6) 425 561
Two or more groups – sensitivity and specificity 5 (7) 688 520
Sample type      
Antigen tests      
NP only 3 (3) 434 271
NP+OP 5 (2) 328 147
Mixed (3 or more types) 0 (0) n/a n/a
Rapid molecular tests      
NP only 6 (7) 529 595
NP+OP 1 (1) 88 84
Mixed (3 or more types) 4 (5) 496 402
NP: nasopharyngeal; OP: oropharyngeal
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